caffeine has been researched along with Anesthesia Related Hyperthermia in 383 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The most commonly used laboratory test for predicting malignant hyperthermia susceptibility is the caffeine halothane contracture test." | 9.07 | Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry. ( Bunn, JS; Diaz, M; Landis, JR; Larach, MG, 1992) |
| " The center followed the diagnostic protocols of the North America MH Group, in which the contractures of biopsies from the vastus lateralis muscle are analyzed after exposure to caffeine and halothane (CHCT)." | 7.76 | Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil. ( Abreu, AV; Aguiar, MI; Cardoso, LA; Carmo, PL; Cunha, LB; Matos, AR; Sudo, RT; Trachez, MM; Zapata-Sudo, G, 2010) |
| "The caffeine-halothane contracture test (CHCT) is the only recognized laboratory test to diagnose malignant hyperthermia (MH)." | 7.70 | The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. ( Allen, GC; Kunselman, AR; Larach, MG, 1998) |
| "Contracture responses of intact cut masseter and vastus bundles (non-skinned) do not differ with respect to caffeine and halothane." | 7.70 | Caffeine- or halothane-induced contractures of masseter muscle are similar to those of vastus muscle in normal humans. ( Antognini, JF; Gronert, GA; Melton, AT, 1999) |
| " We evaluated whether toxic concentrations of cocaine altered the in vitro muscle response to halothane during contracture tests for MH." | 7.69 | Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia. ( Brum, JM; DeBoer, GE; Mitsumoto, H; Sato, N, 1995) |
| "The in vitro halothane and caffeine contracture tests have been performed on muscle tissue from six survivors of the neuroleptic malignant syndrome." | 7.67 | Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests. ( Adnet, P; Guevart, E; Krivosic-Horber, R; Lestavel, P; Theunynck, D, 1987) |
| "Using the skinned fiber preparation, the response to caffeine was studied on the skeletal muscle of malignant hyperthermia or other neuromuscular diseases." | 7.66 | Malignant hyperthermia and related neuromuscular diseases: caffeine contracture of the skinned muscle fibers. ( Ishihara, T; Nonaka, I; Sugita, H; Sunohara, N; Takagi, A, 1983) |
| "We evaluated six boys who had developed isolated masseter muscle spasm following intravenous succinylcholine." | 7.66 | Masseter spasm induced by succinylcholine in children: contracture testing for malignant hyperthermia: report of six cases. ( Flewellen, EH; Nelson, TE, 1982) |
| "He presented clinical features of malignant hyperthermia (MH), and had masseter spasm and elevated body temperature (38." | 5.29 | Malignant hyperthermia in a patient with Becker muscular dystrophy: dystrophin analysis and caffeine contracture study. ( Goto, K; Hamano, K; Iida, K; Mizusawa, H; Ohkoshi, N; Shoji, S; Sugishita, Y; Takagi, A; Toyama, M; Yoshizawa, T, 1995) |
| "The association of malignant hyperthermia (MH) with neuromuscular disorders has been recognized since 1970." | 5.27 | Halothane-caffeine contracture testing in neuromuscular diseases. ( Fletcher, JE; Heiman-Patterson, TD; Rosenberg, H; Tahmoush, AJ, 1988) |
| "The most commonly used laboratory test for predicting malignant hyperthermia susceptibility is the caffeine halothane contracture test." | 5.07 | Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry. ( Bunn, JS; Diaz, M; Landis, JR; Larach, MG, 1992) |
| " However, experts worldwide agree that the only reference test to this day remains the in vitro halothane caffeine contracture tests." | 4.77 | [Screening tests for malignant hyperthermia susceptibility]. ( Adnet, P; Krivosic-Horber, R, 1989) |
| " The center followed the diagnostic protocols of the North America MH Group, in which the contractures of biopsies from the vastus lateralis muscle are analyzed after exposure to caffeine and halothane (CHCT)." | 3.76 | Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil. ( Abreu, AV; Aguiar, MI; Cardoso, LA; Carmo, PL; Cunha, LB; Matos, AR; Sudo, RT; Trachez, MM; Zapata-Sudo, G, 2010) |
| " Exposure of CASQ1-null mice to either 2% halothane or heat stress triggers lethal episodes characterized by whole-body contractures, elevated core temperature, and severe rhabdomyolysis, which are prevented by prior dantrolene administration." | 3.75 | Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice. ( Canato, M; Dainese, M; Dirksen, RT; Lyfenko, AD; Paolini, C; Protasi, F; Quarta, M; Reggiani, C, 2009) |
| " Genetic screening of a 5-generation Brazilian family with a history of MH-related deaths and a previous MH diagnosis by the caffeine halothane contracture test (CHCT) in some individuals was performed using restriction and sequencing analysis." | 3.75 | Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene. ( Amoedo, ND; Cunha, LB; Matos, AR; Rumjanek, FD; Sambuughin, N; Sudo, RT; Zapata-Sudo, G, 2009) |
| "The caffeine-halothane contracture test (CHCT) is the only recognized laboratory test to diagnose malignant hyperthermia (MH)." | 3.70 | The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. ( Allen, GC; Kunselman, AR; Larach, MG, 1998) |
| "Contracture responses of intact cut masseter and vastus bundles (non-skinned) do not differ with respect to caffeine and halothane." | 3.70 | Caffeine- or halothane-induced contractures of masseter muscle are similar to those of vastus muscle in normal humans. ( Antognini, JF; Gronert, GA; Melton, AT, 1999) |
| " Diagnosis is based on in vitro muscle contracture in response to halothane and/or caffeine exposure." | 3.70 | [Malignant hyperthermia susceptibility in 3 patients with malignant neuroleptic syndrome]. ( Bahia, VS; Marchiori, PE; Oliveira, RA; Scaff, M; Silva, HC; Tsanaclis, AM, 2000) |
| " We evaluated whether toxic concentrations of cocaine altered the in vitro muscle response to halothane during contracture tests for MH." | 3.69 | Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia. ( Brum, JM; DeBoer, GE; Mitsumoto, H; Sato, N, 1995) |
| " The halothane/caffeine contracture test was performed on the biopsied muscle." | 3.69 | Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy. ( Britt, BA; Carr, AS; Cunliffe, M; Lerman, J; McLeod, ME, 1995) |
| " In vitro, human MHS muscle samples were exposed to propofol and changes in (a) baseline tension and (b) contracture tension on exposure to halothane and caffeine were measured." | 3.68 | Propofol is a 'safe' anaesthetic agent in malignant hyperthermia susceptible patients. ( Couchman, KG; McKenzie, AJ; Pollock, N, 1992) |
| "The in vitro contracture test determines the sensitivity of freshly obtained skeletal muscle specimens to caffeine or halothane applied to a bathing solution." | 3.68 | In vitro contracture testing for determination of susceptibility to malignant hyperthermia: a methodologic update. ( Gallagher, WJ; Iaizzo, PA; Wedel, DJ, 1991) |
| " In the present study the cytoplasmic Ca2+ concentrations of lymphocytes were monitored with indo-1 in 14 control subjects (nine fasted and five nonfasted) and five fasted MH susceptible and three fasted nonsusceptible patients, diagnosed by the halothane and caffeine contracture tests." | 3.68 | Importance of fasting in the lymphocyte calcium test for malignant hyperthermia. ( Allen, GC; Conner, GE; Fletcher, JE; Huggins, FJ; Rosenberg, H, 1990) |
| "In vitro contracture tests for susceptibility to malignant hyperthermia (MH) were performed with halothane and caffeine in 34 patients, according to the protocol of the European MH Group." | 3.68 | Influence of salbutamol on the in vitro muscle response to caffeine and halothane in malignant hyperthermia. ( Bendixen, D; Ording, H, 1990) |
| " In order to provide additional evidence, all eight patients had vastus lateralis muscle biopsies with subsequent caffeine-halothane contracture studies performed." | 3.68 | Malignant hyperthermia in the otolaryngologic patient: prospective anesthetic and surgical management of eight children. ( Dubrow, TJ; Dudley, JP; Reynolds, R, 1990) |
| " The in vitro halothane-caffeine contracture tests are the most reliable method of identifying individuals susceptible to MH." | 3.67 | The association between the neuroleptic malignant syndrome and malignant hyperthermia. ( Adamantidis, MM; Adnet, PJ; Adnet-Bonte, CA; Dupuis, BA; Haudecoeur, G; Krivosic-Horber, RM; Saulnier, F, 1989) |
| "The results are reported of the contracture test obtained by using the calcium ionophore A 23187 (Calcimycin) in two patients, the son (A) and the mother (B)." | 3.67 | [Contracture test with ionophore A 23187 for the diagnosis of malignant hyperthermia]. ( Gascard, JP; Kozak-Reiss, G; Laxenaire, MC; Moeller, R, 1986) |
| " Halothane-caffeine contracture tests, interpreted in accordance with the criteria of the European Group on Malignant Hyperthermia, yielded the following results: 13 positive (MHS), 10 negative (MHN), 4 equivocal (MHE)." | 3.67 | [Tests of contracture and sensitivity to malignant hyperthermia in 27 patients]. ( Adamantidis, M; Adnet, P; Guévart, E; Krivosic, I; Krivosic-Horber, R; Theunynck, D, 1988) |
| "The in vitro halothane and caffeine contracture tests have been performed on muscle tissue from six survivors of the neuroleptic malignant syndrome." | 3.67 | Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests. ( Adnet, P; Guevart, E; Krivosic-Horber, R; Lestavel, P; Theunynck, D, 1987) |
| "Seventy-seven patients who developed masseter muscle rigidity (MMR) after receiving succinylcholine to facilitate tracheal intubation were evaluated for malignant hyperthermia (MH) susceptibility by in vitro halothane and caffeine contracture tests." | 3.67 | Masseter muscle rigidity and malignant hyperthermia susceptibility. ( Fletcher, JE; Rosenberg, H, 1986) |
| "Using the skinned fiber preparation, the response to caffeine was studied on the skeletal muscle of malignant hyperthermia or other neuromuscular diseases." | 3.66 | Malignant hyperthermia and related neuromuscular diseases: caffeine contracture of the skinned muscle fibers. ( Ishihara, T; Nonaka, I; Sugita, H; Sunohara, N; Takagi, A, 1983) |
| "We evaluated six boys who had developed isolated masseter muscle spasm following intravenous succinylcholine." | 3.66 | Masseter spasm induced by succinylcholine in children: contracture testing for malignant hyperthermia: report of six cases. ( Flewellen, EH; Nelson, TE, 1982) |
| " Using muscle from patients susceptible to malignant hyperpyrexia in vitro, it has been demonstrated that muscle contracture can occur with procaine on its own, and in one patient the halothane-induced contracture was potentiated by procaine." | 3.65 | An evaluation of procaine in the treatment of malignant hyperpyrexia. ( Clarke, IM; Ellis, FR, 1975) |
| "Halothane-induced contractures in isolated muscle fibers from swine susceptible to malignant hyperthermia (MHS) were significantly less when fibers were incubated in KRB plus 6." | 3.65 | Porcine malignant hyperthermia: effect of dantrolene sodium on in-vitro halothane-induced contraction of susceptible muscle. ( Anderson, IL; Jones, EW, 1976) |
| "Individuals susceptible to malignant hyperpyrexia have muscle with heightened sensitivity to halothane, caffeine, succinylcholine, potassium chloride, and temperature change." | 2.64 | Identification of susceptibility to malignant hyperpyrexia. ( Denborough, MA; Moulds, RF, 1974) |
| "Malignant hyperthermia is a hypermetabolic syndrome that appears in susceptible patients after exposure to certain anaesthetic drugs (succinylcholine, inhalation anaesthetics)." | 2.55 | Clinical protocol for the management of malignant hyperthermia. ( Alsina, E; Del Blanco, B; Domínguez, A; García, A; Guerrero, JL; Kollmann-Camaiora, A; Yepes, MJ, 2017) |
| "DNA-based diagnosis for malignant hyperthermia (MH) is an attractive proposition, because it could replace the invasive and morbid caffeine-halothane/in vitro contracture tests of skeletal muscle biopsy tissue." | 2.50 | DNA testing for malignant hyperthermia: the reality and the dream. ( Stowell, KM, 2014) |
| "In human muscle fibers from malignant hyperthermia susceptible patients, such Ca(2+) waves occur when 1mM halothane is applied at physiological [Mg(2+)](i)." | 2.44 | Defective Mg2+ regulation of RyR1 as a causal factor in malignant hyperthermia. ( Duke, AM; Steele, DS, 2007) |
| "The problem of malignant hyperthermia may become worse in the near future due to changes in the population brought about by immigration." | 2.44 | [Anesthesia in malignant hyperthermia]. ( Ortiz Gómez, JR, 2008) |
| "When malignant hyperthermia-does occur in the operating room, prompt recognition and treatment usually prevent a potentially fatal outcome." | 2.40 | Malignant hyperthermia. ( Adnet, P; Ben Abraham, R; Glauber, V; Perel, A, 1998) |
| "Most patients with malignant hyperthermia susceptibility diagnosed by the in vitro caffeine-halothane contracture test (CHCT) develop excessive force in response to halothane but not caffeine (halothane-hypersensitive)." | 1.91 | Distinct pathophysiological characteristics in developing muscle from patients susceptible to malignant hyperthermia. ( Figueroa, L; Ibarra-Moreno, CA; Kraeva, N; Manno, C; Riazi, S; Rios, E; Tammineni, ER, 2023) |
| "Exertional heat illness (EHI) and malignant hyperthermia (MH) are life threatening conditions associated with muscle breakdown in the setting of triggering factors including volatile anesthetics, exercise, and high environmental temperature." | 1.72 | Variants in ASPH cause exertional heat illness and are associated with malignant hyperthermia susceptibility. ( Celik, A; Dirksen, RT; Dowling, JJ; Endo, Y; Gardner, L; Groom, L; Hamilton, SL; Hopkins, PM; Jung, SY; Kraeva, N; Lee, CS; Riazi, S; Shaw, MA, 2022) |
| "The variable clinical presentation of malignant hyperthermia (MH), a disorder of calcium signalling, hinders its diagnosis and management." | 1.51 | Abnormal calcium signalling and the caffeine-halothane contracture test. ( Figueroa, L; Kraeva, N; Manno, C; Riazi, S; Ríos, E; Toro, S, 2019) |
| "We identified 43 malignant hyperthermia families carrying one of the six RYR1 variants." | 1.46 | Assessing the pathogenicity of RYR1 variants in malignant hyperthermia. ( Allen, PD; Bilmen, JG; Booms, P; Daly, C; Hopkins, PM; Merritt, A; Miller, DM; Shaw, MA; Steele, DS; Stowell, KM, 2017) |
| "Hydrogen sulfide is an endogenous gasotransmitter and its mechanism of action involves activation of ATP-sensitive K(+) channels and phosphodiesterase inhibition." | 1.43 | Cystathionine β-synthase-derived hydrogen sulfide is involved in human malignant hyperthermia. ( Andria, B; Attanasio, C; Bucci, M; Calderone, V; Cantalupo, A; Cirino, G; Di Martino, A; Ianaro, A; Mancini, A; Panza, E; Savoia, G; Vellecco, V, 2016) |
| "Several malignant hyperthermia-associated neuromuscular diseases are associated with an altered connective tissue composition." | 1.40 | Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia. ( Hoppe, K; Jäger, H; Klingler, W; Lehmann-Horn, F; Schleip, R, 2014) |
| "The clinical symptoms resemble malignant hyperthermia (MH), which may lead to mistreatment of the patient." | 1.39 | In vitro muscle contracture investigations on the malignant hyperthermia like episodes in myotonia congenita. ( Adolph, O; Chaiklieng, S; Hoppe, K; Jurkat-Rott, K; Klingler, W; Lehmann-Horn, F, 2013) |
| "Identifying patients predisposed to malignant hyperthermia is done through the Ca-induced Ca release test in Japan." | 1.37 | Analysis of human cultured myotubes responses mediated by ryanodine receptor 1. ( Hamada, H; Kawamoto, M; Kobayashi, M; Migita, T; Mukaida, K; Yuge, O, 2011) |
| "To diagnose malignant hyperthermia (MH) susceptibility, muscle bundles are exposed to halothane and caffeine." | 1.37 | Sevoflurane as a potential replacement for halothane in diagnostic testing for malignant hyperthermia susceptibility: results of a preliminary study. ( Anetseder, M; Hartung, E; Metterlein, T; Roewer, N; Schuster, F, 2011) |
| "In vitro contracture testing to diagnose malignant hyperthermia (MH) susceptibility requires a muscle biopsy, which may be associated with severe side effects for the patient." | 1.35 | An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study. ( Anetseder, M; Kranke, P; Metterlein, T; Muellenbach, RM; Negele, S; Roewer, N; Schuster, F; Schwemmer, U, 2008) |
| " We conclude firstly that propofol is safe for individuals with predisposition to malignant hyperthermia when it is used within the recommended clinical dosage range, and secondly that its mode of action upon ryanodine receptors is likely to be different from that of caffeine." | 1.35 | Effects of propofol on calcium homeostasis in human skeletal muscle. ( Hamada, H; Kawamoto, M; Kobayashi, M; Migita, T; Mukaida, K; Nishino, I; Yuge, O, 2009) |
| " Reproducible shifts in the dose-response of skeletal muscle to caffeine and halothane are the basis of the current in vitro diagnostic caffeine-halothane contracture test." | 1.33 | Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis. ( Bina, S; Bünger, R; Cowan, G; Karaian, J; Mongan, P; Muldoon, S, 2006) |
| " MH susceptibility leads to a leftward shift of the dose-response curve for IM lactate after local injection of halothane and caffeine." | 1.33 | The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. ( Anetseder, M; Hager, M; Müller, R; Roewer, N; Schöll, H; Schuster, F, 2006) |
| "We report the first case of malignant hyperthermia, verified by caffeine-halothane contracture test and genetic testing, in a Chinese patient." | 1.33 | Malignant hyperthermia in China. ( Guo, XY; Huang, YG; Luo, AL; Ren, HZ; Wang, YL; Xu, ZH; Ye, TH; Zhang, X, 2006) |
| "To determine whether malignant hyperthermia (MH) susceptibility in a Canadian pedigree is associated with a mutation in the ryanodine receptor subtype 1 (RYR1) gene, the complete RYR1 transcript obtained from the leukocytes of one MH-susceptible family member was sequenced, using a newly developed protocol." | 1.32 | Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript. ( Du, G; Kraev, A; Kraev, N; Loke, JC; MacLennan, DH; Patel, L; Sharma, P, 2003) |
| "The diagnosis of susceptibility to malignant hyperthermia (MH) is currently performed on muscle biopsies subjected to halothane-caffeine in vitro contracture tests (IVCTs)." | 1.32 | Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. ( Bendahan, D; Cozzone, PJ; Ghattas, B; Guis, S; Kozak-Ribbens, G; Lunardi, J; Mattei, JP; Monnier, N, 2004) |
| "These results suggest that human malignant hyperthermia (MH) is associated with reduced inhibition of the RYR by (i) cytosolic Mg(2+) and (ii) SR Ca(2+) depletion." | 1.31 | Effects of Mg(2+) and SR luminal Ca(2+) on caffeine-induced Ca(2+) release in skeletal muscle from humans susceptible to malignant hyperthermia. ( Duke, AM; Hopkins, PM; Steele, DS, 2002) |
| "The diagnosis of malignant hyperthermia susceptibility relies on the in vitro contracture test on skeletal muscle." | 1.31 | Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane. ( Dirksen, R; Gielen, MJ; Snoeck, MM; Tangerman, A; van Egmond, J, 2000) |
| "The diagnostic outcomes of tests for malignant hyperthermia susceptibility were compared between two laboratories by using muscle tissue from the same patients." | 1.31 | Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility. ( Bendixen, D; Islander, G; Ording, H; Ranklev-Twetman, E, 2000) |
| "Whether these complications are malignant hyperthermia (MH) or not has several times been discussed." | 1.31 | [Malignant hyperthermia of Duchenne muscular dystrophy: application of clinical grading scale and caffeine contracture of skinned muscle fibers]. ( Takagi, A, 2000) |
| "Central core disease (CCD) and nemaline myopathy (NM) are congenital myopathies for which differential diagnosis is often based on the presence either of cores or rods." | 1.31 | An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. ( Fardeau, M; Lerale, J; Lunardi, J; MacLennan, DH; Monnier, N; Nivoche, Y; Qi, D; Romero, NB, 2000) |
| "Xenon 70% did not cause an increase in baseline tension of any MH-susceptible muscle specimen in contrast to halothane and caffeine." | 1.31 | Xenon does not induce contracture in human malignant hyperthermia muscle. ( Baur, CP; Froeba, G; Georgieff, M; Jurkat-Rott, K; Klingler, W; Lehmann-Horn, F; Marx, T; Schoch, E, 2000) |
| "The determination of susceptibility to malignant hyperthermia (MH) by genetic investigation is a controversial issue because of the genetic heterogeneity of this disorder." | 1.31 | Homozygous and heterozygous Arg614Cys mutations (1840C-->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family. ( Deutrich, C; Froster, UG; Olthoff, D; Rueffert, H; Thamm, B, 2001) |
| "Susceptibility to malignant hyperthermia is diagnosed by contracture test, which requires an open muscle biopsy sample." | 1.31 | Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. ( Anetseder, M; Hager, M; Müller, CR; Roewer, N, 2002) |
| " MHEh muscles revealed a dose-response curve similar to that found in MHN specimens." | 1.30 | Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol. ( Bittner, RE; Fricker, R; Gilly, H; Kress, HG; Musat, I; Steinbereithner, K, 1997) |
| "Chlorocresol was demonstrated to be a potent activator of Ca++ release from skeletal muscle sarcoplasmic reticulum." | 1.30 | [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients]. ( Adnet, PJ; Ben-Abraham, R; Haudcoeur, G; Krivosic-Horber, RM; Perel, A, 1997) |
| "The association between malignant hyperthermia (MH) and neuromuscular disorders is controversial." | 1.30 | Dystrophin deficient mdx muscle is not prone to MH susceptibility: an in vitro study. ( Bittner, RE; Gilly, H; Mader, N, 1997) |
| "Regulation of muscle contraction is abnormal in Thoroughbreds with RER." | 1.30 | Abnormal regulation of muscle contraction in horses with recurrent exertional rhabdomyolysis. ( Balog, EM; Gallant, EM; Lentz, LR; Mickelson, JR; Valberg, SJ, 1999) |
| " The type of fibres (type I: oxidative, slow; type II: glycolytic, fast) were determined with strontium dose-response curves." | 1.30 | [Caffeine skinned fiber tension test: application to the diagnosis of susceptibility to malignant hyperthermia]. ( Adnet, P; Börtlein, ML; Etchrivi, T; Haudecoeur, G; Krivosic-Horber, R; Nivoche, Y; Tavernier, B, 1999) |
| "Anaesthesia-induced malignant hyperthermia (MH) may be caused by specific gene defects in the skeletal muscle ryanodine receptor." | 1.29 | Genotype and phenotype relationships for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia. ( Fletcher, JE; Hubert, M; Levitt, RC; Rosenberg, H; Tripolitis, L; Vita, GM, 1995) |
| "During human and porcine malignant hyperthermia (MH), cardiac dysrhythmias and altered myocardial function can be observed." | 1.29 | Abnormal action potential responses to halothane in heart muscle isolated from malignant hyperthermia-susceptible pigs. ( Greim, C; Roewer, N; Rumberger, E; Schulte am Esch, J, 1995) |
| "He presented clinical features of malignant hyperthermia (MH), and had masseter spasm and elevated body temperature (38." | 1.29 | Malignant hyperthermia in a patient with Becker muscular dystrophy: dystrophin analysis and caffeine contracture study. ( Goto, K; Hamano, K; Iida, K; Mizusawa, H; Ohkoshi, N; Shoji, S; Sugishita, Y; Takagi, A; Toyama, M; Yoshizawa, T, 1995) |
| "The altered caffeine sensitivity of malignant hyperthermia-susceptible (MHS) muscle contracture is one basis of the diagnostic test for this syndrome." | 1.29 | Caffeine stimulation of malignant hyperthermia-susceptible sarcoplasmic reticulum Ca2+ release channel. ( Louis, CF; Mickelson, JR; Shomer, NH, 1994) |
| "The identification of disposition for malignant hyperthermia (MH) is performed by the halothane-caffeine contracture test in skeletal muscle." | 1.29 | [High purity ryanodine for in vitro diagnosis of malignant hyperthermia]. ( Lenzen, C; Roewer, N; Rumberger, R; Scholz, J; Schulte am Esch, J; Steinfath, M; Wappler, F, 1993) |
| "Caffeine sensitivity was defined as the threshold concentration inducing more than 10% of the maximal tension obtained with a calcium 1." | 1.29 | Fiber-type caffeine sensitivities in skinned muscle fibers from humans susceptible to malignant hyperthermia. ( Adamantidis, MM; Adnet, PJ; Bello, N; Bromberg, NL; Haudecoeur, G; Krivosic Horber, RM; Krivosic, I; Reyford, H, 1993) |
| "Malignant hyperthermia is a seemingly rare genetic myopathy." | 1.29 | Malignant hyperthermia in the otology patient: the UCLA experience. ( Blackwell, KE; Wackym, PA, 1994) |
| "Halothane in Krebs was assayed by high pressure liquid chromatography." | 1.29 | Caffeine-halothane accuracy in MH testing. ( Antognini, JF; Chun, K; Gronert, GA; Hwang, F, 1995) |
| "The defect in malignant hyperthermia (MH) alters the binding of [3H]ryanodine to the Ca(2+)-release channel by increasing its apparent affinity for the binding site." | 1.28 | [3H]ryanodine as a probe of changes in the functional state of the Ca(2+)-release channel in malignant hyperthermia. ( Hamilton, SL; Hawkes, MJ; Nelson, TE, 1992) |
| "1." | 1.28 | W-7, a calmodulin antagonist, and contracture of malignant hyperthermia susceptible skeletal muscle. ( Holland, M; Lee, JC; Williams, JH, 1992) |
| "2." | 1.28 | Propofol anaesthesia in malignant hyperpyrexia susceptible swine. ( Denborough, MA; Foster, PS; Hopkinson, KC, 1992) |
| "Pre-treatment with ryanodine did not change the calcium signal brought about by halothane or ionomycin." | 1.28 | [Effects of halothane, caffeine and ryanodine on the intracellular calcium store in blood mononuclear cells]. ( Endo, M; Iino, M; Kawana, Y; Oyamada, H, 1992) |
| "Until our malignant hyperthermia diagnostic center was opened, such tests could not be performed in Israel." | 1.28 | [In vitro diagnosis of malignant hyperpyrexia syndrome]. ( Eldar, I; Glauber, V; Goldberg, G; Perel, A, 1991) |
| "Platelets from normal and malignant hyperthermia (MH)-susceptible pigs were evaluated for differences in 45calcium uptake in the absence or presence of caffeine (2-16 mM), halothane (0." | 1.28 | Calcium handling by platelets from normal and malignant hyperthermia-susceptible pigs. ( Bonk, KR; Brooks, RR; Carpenter, JF; Miller, KE, 1991) |
| "The inheritance of malignant hyperthermia susceptibility is thought to be autosomal dominant and the incidence could be as high as 1:10,000." | 1.28 | [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland]. ( Censier, K; Drewe, J; Frei, F; Rothenbühler, JM; Seeberger, MD; Urwyler, A, 1991) |
| "Caffeine sensitivity was studied in chemically skinned muscle fibers from vastus lateralis muscle obtained by biopsy during reconstructive knee surgery from 15 otherwise healthy young individuals." | 1.28 | Fiber-type specific caffeine sensitivities in normal human skinned muscle fibers. ( Andrish, JT; Bunge, G; Cruse, RP; DeBoer, GE; Mitsumoto, H; Tetzlaff, JE, 1990) |
| " In six MH(-) patients with previous masseter muscle rigidity, no adverse reactions occurred in response to volatile anesthetic agents." | 1.28 | Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility. ( Allen, GC; Fletcher, JE; Rosenberg, H, 1990) |
| "Although an association between malignant hyperthermia (MH) and congenital abnormalities has been recorded, no prospective study has been attempted to investigate this relationship." | 1.28 | An association between certain congenital abnormalities and the malignant hyperthermia trait. ( Gericke, GS; Isaacs, H, 1990) |
| " In contrast, propranolol shifted the caffeine dose-response curve to the right and significantly increased the caffeine threshold in the MHS group." | 1.28 | Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle. ( Ording, H, 1989) |
| "Midazolam is a water soluble benzodiazepine of interest to the anaesthetist for use as a premedicant and for induction of anaesthesia." | 1.27 | Effects of midazolam on directly stimulated muscle biopsies from control and malignant hyperthermia positive patients. ( Fletcher, JE; Hilf, M; Rosenberg, H, 1984) |
| "The caffeine test was positive in 68% of MHS patients, 0." | 1.27 | Investigation of malignant hyperthermia in Denmark and Sweden. ( Fletcher, R; Ording, H; Ranklev, E, 1984) |
| "A European Malignant Hyperpyrexia Group has been formed to facilitate exchange of information between centres performing in vitro muscle testing for malignant hyperpyrexia susceptibility." | 1.27 | A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. ( , 1984) |
| "Since the cellular defect of malignant hyperthermia (MH) may occur in tissues other than muscle and since platelets share certain contractile characteristics with muscle cells, testing platelets has been suggested as a way to diagnose susceptibility to MH." | 1.27 | Halothane-induced ATP depletion in platelets from patients susceptible to malignant hyperthermia and from controls. ( Giger, U; Kaplan, RF, 1983) |
| "The halothane-induced increase in [Ca2+]i required extracellular calcium ions." | 1.27 | Anaesthetic-induced increase in ionised calcium in blood mononuclear cells from malignant hyperthermia patients. ( Britt, BA; Elliott, ME; Frodis, W; Klip, A; Pegg, W; Scott, E, 1987) |
| "Trapezius muscle from normal and malignant hyperthermia (MH) pigs was used to investigate the effects of halothane on contractile properties and on the calcium transport system of isolated surface membranes." | 1.27 | Effect of halothane on the Ca2+-transport system of surface membranes isolated from normal and malignant hyperthermia pig skeletal muscle. ( Kozak-Reiss, G; Rock, E, 1987) |
| "Malignant hyperthermia is a seemingly rare genetic myopathy." | 1.27 | Malignant hyperthermia in plastic surgery. ( Abdul-Rasool, IH; Dubrow, TJ; Lesavoy, MA; Wackym, PA, 1988) |
| "1." | 1.27 | Calmodulin-antagonist drugs and porcine malignant hyperpyrexia. ( Collins, SP; Denborough, MA; White, MD, 1988) |
| "The association of malignant hyperthermia (MH) with neuromuscular disorders has been recognized since 1970." | 1.27 | Halothane-caffeine contracture testing in neuromuscular diseases. ( Fletcher, JE; Heiman-Patterson, TD; Rosenberg, H; Tahmoush, AJ, 1988) |
| "A case of malignant hyperthermia in a black South African, in whom the reaction only became evident in the postoperative period, is reported." | 1.27 | Malignant hyperthermia in a black adolescent. A case report. ( Couper, JL; Lombard, TP, 1988) |
| "The acute malignant hyperthermia crisis appears to be mediated by a sudden and sustained rise in the concentration of sarcoplasmic calcium, leading to a prolonged muscle contraction." | 1.27 | Abnormal relaxation rates in subjects susceptible to malignant hyperthermia. ( Henriksson, KG; Lennmarken, C; Rutberg, H, 1987) |
| "In vitro tests for the diagnosis of malignant hyperthermia susceptibility were performed in 105 patients and 20 normal controls according to the protocol of the European MH Group." | 1.27 | In vitro diagnosis of susceptibility to malignant hyperthermia: comparison between dynamic and static halothane and caffeine tests. ( Ording, H; Skovgaard, LT, 1987) |
| "To diagnose malignant hyperthermia susceptibility (MHS), caffeine and halothane contracture tests were performed on six patients." | 1.27 | [Detection of peranesthetic malignant hyperthermia by muscle contracture tests and NMR spectroscopy]. ( Gascard, JP; Kozak-Reiss, G; Redouane-Bénichou, K, 1986) |
| "Ten additional patients had other muscle disorders (central core disease, hyperkalemic periodic paralysis, and Duchenne's muscular dystrophy) and abnormal IVCTs; six of the ten had elevated CK levels." | 1.27 | Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia. ( Brownell, AK; Paasuke, RT, 1986) |
| "The father was found to be malignant hyperpyrexia-susceptible." | 1.27 | Malignant hyperpyrexia and sudden death. ( Fletcher, R; Krantz, P; Ranklev, E, 1985) |
| "In a report of two patients who died of malignant hyperthermia, muscle adenylate kinase deficiency was identified in the father and brother of the deceased." | 1.26 | Adenylate kinase deficiency and malignant hyperthermia. ( Britt, BA; Cerri, CG; Willner, JH; Wood, DS, 1981) |
| "This model for malignant hyperpyrexia resembles the naturally occurring disease more closely than several preceding pharmacologic models." | 1.26 | A laboratory animal model for malignant hyperpyrexia. ( Durbin, CG; Rosenberg, H, 1979) |
| "Some non-rigid Malignant Hyperthermia Susceptible (MHS) patients have a greater than normal incidence of fractures." | 1.26 | In vivo neutron activation analysis for bone calcium (INVAA) in malignant hyperthermia susceptible patients. ( Britt, BA; Harrison, JE; McNeill, KG, 1979) |
| "In this Research Conference we define malignant hyperthermia, present its brief history, and describe the diagnostic procedures and directions of research in our laboratory." | 1.26 | Malignant hyperthermia: diagnosis, treatment and investigations of a skeletal muscle lesion. ( Flewellen, EH; Nelson, TE, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 125 (32.64) | 18.7374 |
| 1990's | 133 (34.73) | 18.2507 |
| 2000's | 78 (20.37) | 29.6817 |
| 2010's | 37 (9.66) | 24.3611 |
| 2020's | 10 (2.61) | 2.80 |
| Authors | Studies |
|---|---|
| Upchurch, WJ | 1 |
| Iaizzo, PA | 6 |
| Bin, X | 1 |
| Wang, B | 1 |
| Tang, Z | 1 |
| Noda, Y | 2 |
| Mukaida, K | 8 |
| Miyoshi, H | 4 |
| Nakamura, R | 2 |
| Yasuda, T | 6 |
| Saeki, N | 1 |
| Nishino, I | 4 |
| Tsutsumi, YM | 2 |
| Carlson, KJ | 1 |
| Sun, SA | 1 |
| Swan, C | 1 |
| Koenig, M | 1 |
| Derkay, CS | 1 |
| Endo, Y | 1 |
| Groom, L | 2 |
| Celik, A | 1 |
| Kraeva, N | 8 |
| Lee, CS | 1 |
| Jung, SY | 1 |
| Gardner, L | 1 |
| Shaw, MA | 5 |
| Hamilton, SL | 4 |
| Hopkins, PM | 16 |
| Dirksen, RT | 6 |
| Riazi, S | 8 |
| Dowling, JJ | 1 |
| Moon, YJ | 1 |
| Park, J | 1 |
| Kim, JR | 1 |
| Lee, SY | 1 |
| Lee, J | 1 |
| Cho, YG | 1 |
| Kim, DS | 1 |
| Figueroa, L | 3 |
| Manno, C | 2 |
| Ibarra-Moreno, CA | 1 |
| Tammineni, ER | 1 |
| Rios, E | 3 |
| Ibarra Moreno, CA | 1 |
| Zvaritch, E | 1 |
| Biesecker, L | 1 |
| Van Petegem, F | 1 |
| Watanabe, T | 1 |
| Narasaki, S | 1 |
| Morio, A | 1 |
| Toyota, Y | 1 |
| Kimura, H | 1 |
| Merritt, A | 1 |
| Booms, P | 2 |
| Miller, DM | 1 |
| Daly, C | 1 |
| Bilmen, JG | 1 |
| Stowell, KM | 3 |
| Allen, PD | 9 |
| Steele, DS | 5 |
| Michelucci, A | 1 |
| Paolini, C | 2 |
| Boncompagni, S | 1 |
| Canato, M | 2 |
| Reggiani, C | 2 |
| Protasi, F | 2 |
| Thompson, SJ | 1 |
| Noseworthy, MD | 1 |
| Rayner, TE | 1 |
| Schneiderman, JE | 1 |
| Cifra, B | 1 |
| Wells, GD | 1 |
| Kondo, T | 2 |
| Otsuki, S | 2 |
| Kanzaki, R | 1 |
| Hamada, H | 6 |
| Kawamoto, M | 6 |
| Nelson, TE | 21 |
| Johannsen, S | 3 |
| Schick, M | 1 |
| Roewer, N | 16 |
| Schuster, F | 8 |
| Türkmeneli, I | 1 |
| Isbary, S | 1 |
| Lopez, JR | 6 |
| Kaura, V | 1 |
| Diggle, CP | 1 |
| Toro, S | 1 |
| Hoppe, K | 3 |
| Lehmann-Horn, F | 13 |
| Chaiklieng, S | 1 |
| Jurkat-Rott, K | 4 |
| Adolph, O | 1 |
| Klingler, W | 6 |
| Larach, MG | 6 |
| Hu, C | 1 |
| Wijeysundera, D | 1 |
| Massey, C | 1 |
| Orlov, D | 1 |
| Keith, J | 1 |
| Rosen, D | 1 |
| Croul, S | 1 |
| Le Guen, M | 1 |
| Houissa, H | 1 |
| Langeron, O | 1 |
| Schleip, R | 1 |
| Jäger, H | 1 |
| Roesl, C | 1 |
| Sato, K | 1 |
| Schiemann, A | 1 |
| Pollock, N | 2 |
| Metterlein, T | 5 |
| Hartung, E | 6 |
| Anetseder, M | 11 |
| Timmins, MA | 1 |
| Rosenberg, H | 27 |
| Sterling, C | 1 |
| Sagui, E | 1 |
| Montigon, C | 1 |
| Abriat, A | 1 |
| Jouvion, A | 1 |
| Duron-Martinaud, S | 1 |
| Canini, F | 2 |
| Zagnoli, F | 1 |
| Bendahan, D | 4 |
| Figarella-Branger, D | 2 |
| Brégigeon, M | 1 |
| Brosset, C | 1 |
| Haraki, T | 3 |
| Vellecco, V | 1 |
| Mancini, A | 1 |
| Ianaro, A | 1 |
| Calderone, V | 1 |
| Attanasio, C | 1 |
| Cantalupo, A | 1 |
| Andria, B | 1 |
| Savoia, G | 1 |
| Panza, E | 1 |
| Di Martino, A | 2 |
| Cirino, G | 1 |
| Bucci, M | 1 |
| Treves, S | 5 |
| Müller, CR | 2 |
| Mögele, S | 1 |
| Schneiderbanger, D | 1 |
| Kollmann-Camaiora, A | 1 |
| Alsina, E | 1 |
| Domínguez, A | 1 |
| Del Blanco, B | 1 |
| Yepes, MJ | 1 |
| Guerrero, JL | 1 |
| García, A | 1 |
| Hack, G | 1 |
| Wearing, S | 1 |
| Zullo, A | 1 |
| Carsana, A | 2 |
| Hager, M | 4 |
| Muellenbach, RM | 2 |
| Wurmb, T | 1 |
| Wunder, C | 1 |
| Negele, S | 1 |
| Kranke, P | 2 |
| Schwemmer, U | 1 |
| Kaufmann, A | 2 |
| Kraft, B | 3 |
| Michalek-Sauberer, A | 4 |
| Weigl, LG | 4 |
| Corona, BT | 1 |
| Rouviere, C | 1 |
| Ingalls, CP | 1 |
| Levano, S | 1 |
| Vukcevic, M | 1 |
| Singer, M | 1 |
| Matter, A | 1 |
| Urwyler, A | 9 |
| Girard, T | 4 |
| Parness, J | 2 |
| Dainese, M | 1 |
| Quarta, M | 1 |
| Lyfenko, AD | 1 |
| Migita, T | 4 |
| Kobayashi, M | 2 |
| Yuge, O | 2 |
| Carpenter, D | 2 |
| Robinson, RL | 3 |
| Quinnell, RJ | 2 |
| Ringrose, C | 2 |
| Hogg, M | 1 |
| Casson, F | 1 |
| Iles, DE | 1 |
| Halsall, PJ | 11 |
| Murakami, N | 1 |
| Finsterer, J | 1 |
| Höftberger, R | 1 |
| Leo, V | 1 |
| Morris, A | 1 |
| Matos, AR | 2 |
| Sambuughin, N | 2 |
| Rumjanek, FD | 1 |
| Amoedo, ND | 1 |
| Cunha, LB | 2 |
| Zapata-Sudo, G | 2 |
| Sudo, RT | 4 |
| Carmo, PL | 1 |
| Trachez, MM | 1 |
| Cardoso, LA | 1 |
| Aguiar, MI | 1 |
| Abreu, AV | 1 |
| Wang, YL | 3 |
| Luo, AL | 3 |
| Tan, G | 1 |
| Cui, XL | 1 |
| Guo, XY | 3 |
| Pirone, A | 1 |
| Schredelseker, J | 1 |
| Tuluc, P | 1 |
| Gravino, E | 1 |
| Fortunato, G | 1 |
| Flucher, BE | 2 |
| Salvatore, F | 1 |
| Grabner, M | 2 |
| Muldoon, SM | 8 |
| Tang, ZZ | 1 |
| Brandom, BW | 2 |
| Bayarsaikhan, M | 1 |
| Bina, S | 6 |
| Lee, HS | 1 |
| Qiu, X | 1 |
| Weindlmayr, M | 1 |
| Kress, HG | 4 |
| Steinboeck, F | 1 |
| Lacava, C | 1 |
| Sgaragli, G | 1 |
| Sipos, E | 1 |
| Höller, C | 1 |
| Fusi, F | 1 |
| Eltit, JM | 1 |
| Bannister, RA | 1 |
| Moua, O | 1 |
| Altamirano, F | 1 |
| Pessah, IN | 4 |
| Molinski, TF | 1 |
| Beam, KG | 1 |
| Sundblom, J | 1 |
| Melberg, A | 1 |
| Rücker, F | 1 |
| Smits, A | 1 |
| Islander, G | 8 |
| Brooks, C | 1 |
| Brown, SL | 1 |
| Ellis, FR | 10 |
| Fiege, M | 4 |
| Wappler, F | 10 |
| Weisshorn, R | 3 |
| Ulrich Gerbershagen, M | 1 |
| Steinfath, M | 4 |
| Schulte Am Esch, J | 7 |
| Wehner, M | 3 |
| Rueffert, H | 7 |
| Koenig, F | 3 |
| Neuhaus, J | 1 |
| Olthoff, D | 8 |
| Duke, AM | 3 |
| Ording, H | 15 |
| Bendixen, D | 6 |
| Ranklev Twetman, E | 3 |
| Sei, Y | 1 |
| Hosoi, E | 1 |
| Gallagher, KL | 1 |
| Wyre, HW | 1 |
| Pudimat, PA | 1 |
| Holman, SJ | 1 |
| Venzon, DJ | 1 |
| Daly, JW | 1 |
| Muldoon, S | 4 |
| Holman, S | 1 |
| Yang, T | 1 |
| Ta, TA | 1 |
| Loke, JC | 1 |
| Kraev, N | 1 |
| Sharma, P | 2 |
| Du, G | 1 |
| Patel, L | 2 |
| Kraev, A | 1 |
| MacLennan, DH | 10 |
| Baur, CP | 3 |
| Censier, K | 5 |
| Doetsch, S | 1 |
| Felleiter, P | 2 |
| Fricker, R | 3 |
| Heffron, JJ | 5 |
| Heytens, L | 5 |
| Nivoche, Y | 4 |
| Tegazzin, V | 6 |
| Tzanova, I | 1 |
| Müller-Reible, C | 1 |
| Textor, Z | 1 |
| Beer, M | 1 |
| Köstler, H | 1 |
| Kagerbauer, E | 1 |
| Kenn, W | 1 |
| Hahn, D | 1 |
| Halliday, NJ | 1 |
| Gallant, EM | 6 |
| Hart, J | 1 |
| Eager, K | 1 |
| Curtis, S | 1 |
| Dulhunty, AF | 2 |
| Deutrich, C | 4 |
| Schober, R | 1 |
| Froster, UG | 4 |
| Ginz, HF | 1 |
| Gillmeister, I | 1 |
| Schummer, C | 1 |
| Hommann, M | 1 |
| Schummer, W | 1 |
| Weiss, RG | 1 |
| O'Connell, KM | 1 |
| Ludwig-Papst, C | 1 |
| Ducreux, S | 1 |
| Zorzato, F | 4 |
| Müller, C | 1 |
| Sewry, C | 1 |
| Muntoni, F | 1 |
| Quinlivan, R | 1 |
| Restagno, G | 1 |
| Guis, S | 1 |
| Monnier, N | 2 |
| Kozak-Ribbens, G | 4 |
| Lunardi, J | 2 |
| Ghattas, B | 2 |
| Mattei, JP | 1 |
| Cozzone, PJ | 4 |
| Linares, N | 2 |
| Halsal, JP | 1 |
| Brini, M | 1 |
| Manni, S | 1 |
| Pierobon, N | 1 |
| Du, GG | 2 |
| Carafoli, E | 1 |
| Litman, RS | 1 |
| Chelu, MG | 1 |
| Goonasekera, SA | 1 |
| Durham, WJ | 1 |
| Tang, W | 1 |
| Lueck, JD | 1 |
| Riehl, J | 1 |
| Zhang, P | 1 |
| Bhattacharjee, MB | 1 |
| Cowan, G | 1 |
| Karaian, J | 1 |
| Mongan, P | 1 |
| Bünger, R | 2 |
| Schöll, H | 1 |
| Müller, R | 1 |
| Gerbershagen, MU | 1 |
| McKinney, LC | 1 |
| Butler, T | 1 |
| Mullen, SP | 1 |
| Klein, MG | 1 |
| Xu, ZH | 2 |
| Ren, HZ | 1 |
| Zhang, X | 1 |
| Huang, YG | 2 |
| Ye, TH | 1 |
| Murayama, T | 1 |
| Oba, T | 1 |
| Hara, H | 1 |
| Wakebe, K | 1 |
| Ikemoto, N | 2 |
| Ogawa, Y | 1 |
| Rydenfelt, K | 1 |
| Ranklev, E | 6 |
| Bodelsson, M | 1 |
| Bross, T | 1 |
| Steinmann, D | 1 |
| Ortiz Gómez, JR | 1 |
| Tollefson, G | 1 |
| Fletcher, JE | 16 |
| Hilf, M | 1 |
| Cerri, CG | 1 |
| Willner, JH | 2 |
| Britt, BA | 19 |
| Wood, DS | 2 |
| Traynor, CA | 1 |
| Van Dyke, RA | 1 |
| Gronert, GA | 8 |
| Flewellen, EH | 7 |
| Arnett, DW | 1 |
| Blanck, TJ | 1 |
| Gruener, RP | 1 |
| Fletcher, R | 5 |
| Eng, GD | 1 |
| Becker, MJ | 1 |
| Takagi, A | 4 |
| Sunohara, N | 1 |
| Ishihara, T | 1 |
| Nonaka, I | 1 |
| Sugita, H | 1 |
| Scott, E | 5 |
| Frodis, W | 6 |
| Clements, MJ | 2 |
| Endrenyi, L | 6 |
| Reed, S | 1 |
| Giger, U | 1 |
| Kaplan, RF | 1 |
| Gloyna, DF | 1 |
| Anderson, IL | 2 |
| Rawstron, RE | 1 |
| Dunlop, DJ | 1 |
| Sporn, P | 2 |
| Godt, RE | 1 |
| Schochet, SS | 1 |
| Brownell, AK | 3 |
| Szabo, M | 1 |
| Mortier, W | 4 |
| Biesel, C | 1 |
| Thompson, RL | 1 |
| Onofrio, BM | 1 |
| Chausmer, AB | 1 |
| Sullivan, JS | 1 |
| Denborough, MA | 16 |
| Kalow, W | 7 |
| Okumura, F | 2 |
| Crocker, BD | 2 |
| Lambert, W | 1 |
| Cerri, C | 1 |
| Britt, B | 2 |
| Mambo, NC | 1 |
| Silver, MD | 1 |
| McLaughlin, PR | 1 |
| Huckell, VF | 1 |
| McEwan, PM | 1 |
| Morch, JE | 1 |
| Otsu, K | 2 |
| Nishida, K | 1 |
| Kimura, Y | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Kamada, T | 1 |
| Tada, M | 1 |
| Tripolitis, L | 1 |
| Hubert, M | 1 |
| Vita, GM | 1 |
| Levitt, RC | 2 |
| Singh, S | 1 |
| Scholz, J | 5 |
| Becker, K | 1 |
| Lenzen, C | 2 |
| Köchling, A | 2 |
| Foster, PS | 6 |
| Greim, C | 1 |
| Rumberger, E | 1 |
| Ohkoshi, N | 1 |
| Yoshizawa, T | 1 |
| Mizusawa, H | 1 |
| Shoji, S | 1 |
| Toyama, M | 1 |
| Iida, K | 1 |
| Sugishita, Y | 1 |
| Hamano, K | 1 |
| Goto, K | 1 |
| Sato, N | 1 |
| Brum, JM | 1 |
| Mitsumoto, H | 2 |
| DeBoer, GE | 2 |
| Bello, N | 2 |
| Adnet, P | 8 |
| Saulnier, F | 2 |
| Lestavel, P | 2 |
| Adnet-Bonte, C | 1 |
| Reyford, H | 4 |
| Etchrivi, T | 2 |
| Tavernier, B | 3 |
| Krivosic-Horber, R | 10 |
| Carr, AS | 1 |
| Lerman, J | 1 |
| Cunliffe, M | 1 |
| McLeod, ME | 1 |
| Ducart, A | 1 |
| Renaud, B | 1 |
| Riou, B | 1 |
| Dickinson, PJ | 1 |
| Sullivan, M | 1 |
| Shomer, NH | 2 |
| Mickelson, JR | 4 |
| Louis, CF | 4 |
| O'Flynn, RP | 1 |
| Shutack, JG | 1 |
| Kaufmann, MA | 1 |
| Drewe, J | 2 |
| Adnet, PJ | 9 |
| Krivosic-Horber, RM | 7 |
| Krivosic, I | 4 |
| Haudecoeur, G | 8 |
| Reyford, HG | 2 |
| Adamantidis, MM | 6 |
| Medahoui, H | 1 |
| Wedel, DJ | 3 |
| Breucking, E | 1 |
| Kaus, SJ | 1 |
| Rockoff, MA | 1 |
| Rumberger, R | 1 |
| Isaacs, H | 2 |
| Badenhorst, M | 1 |
| Bromberg, NL | 1 |
| Krivosic Horber, RM | 1 |
| Rösel, U | 1 |
| Szentkuti, L | 1 |
| Payen, JF | 1 |
| Bosson, JL | 1 |
| Bourdon, L | 2 |
| Jacquot, C | 1 |
| Le Bas, JF | 1 |
| Stieglitz, P | 2 |
| Benabid, AL | 1 |
| Wackym, PA | 2 |
| Blackwell, KE | 1 |
| Serfas, KD | 1 |
| Bose, D | 1 |
| Wrogemann, K | 1 |
| Phillips, MS | 1 |
| Greenberg, CR | 1 |
| Hwang, F | 1 |
| Chun, K | 1 |
| Antognini, JF | 3 |
| Scutari, E | 1 |
| Herrmann-Frank, A | 2 |
| Richter, M | 1 |
| Christiaens, F | 1 |
| Gepts, E | 1 |
| D'Haese, J | 1 |
| Camu, F | 2 |
| Koob, M | 1 |
| Schoemig, P | 1 |
| Krauspe, R | 2 |
| Hogrefe, G | 1 |
| Engelhardt, W | 2 |
| Sessler, DI | 1 |
| Confort-Gouny, S | 2 |
| Owen, VJ | 2 |
| Taske, NL | 2 |
| Lamb, GD | 3 |
| Stewart, AD | 1 |
| O'Brien, PJ | 3 |
| Li, G | 1 |
| Weglinski, MR | 1 |
| Engel, AG | 1 |
| Fagerlund, TH | 3 |
| Ranklev-Twetman, E | 3 |
| Berg, K | 3 |
| Gilly, H | 2 |
| Musat, I | 1 |
| Bittner, RE | 2 |
| Steinbereithner, K | 3 |
| Bachand, M | 1 |
| Vachon, N | 1 |
| Boisvert, M | 1 |
| Mayer, FM | 1 |
| Chartrand, D | 1 |
| Ben-Abraham, R | 1 |
| Haudcoeur, G | 1 |
| Perel, A | 4 |
| Mader, N | 1 |
| Brancadoro, V | 1 |
| Cozzolino, S | 2 |
| Glauber, V | 4 |
| Gonano, EF | 1 |
| Kress, H | 1 |
| Sigurdsson, S | 1 |
| Snoeck, M | 1 |
| Glahn, K | 2 |
| Gardi, T | 1 |
| Fagerlund, T | 1 |
| Tong, J | 2 |
| Oyamada, H | 3 |
| Demaurex, N | 1 |
| Grinstein, S | 1 |
| McCarthy, TV | 3 |
| Laver, DR | 1 |
| Junankar, PR | 1 |
| Ben Abraham, R | 2 |
| Zweig, A | 1 |
| Ummenhofer, W | 1 |
| Roesslein, R | 1 |
| Sutter, PM | 1 |
| Moser, N | 1 |
| Kern, C | 1 |
| Allen, GC | 4 |
| Kunselman, AR | 1 |
| Kasamatsu, Y | 1 |
| Osada, M | 1 |
| Ashida, K | 1 |
| Azukari, K | 1 |
| Yoshioka, K | 1 |
| Ohsawa, A | 1 |
| Winkler, G | 1 |
| Schulte am Esch, JS | 1 |
| Barone, V | 1 |
| Massa, O | 1 |
| Intravaia, E | 1 |
| Bracco, A | 1 |
| Sorrentino, V | 1 |
| Aggarwal, M | 1 |
| Montes, A | 1 |
| Ramos, R | 1 |
| Trillo, L | 1 |
| Silva, T | 1 |
| Puig, MM | 1 |
| Wieland, SJ | 2 |
| Stewart, SL | 1 |
| Twetman, ER | 1 |
| Etchrivi, TS | 1 |
| Diallo, A | 1 |
| Lentz, LR | 2 |
| Valberg, SJ | 1 |
| Balog, EM | 2 |
| Melton, AT | 2 |
| Börtlein, ML | 1 |
| Richter, A | 2 |
| Bellon, L | 1 |
| Lehane, M | 2 |
| Georgieff, M | 2 |
| Snoeck, MM | 1 |
| Gielen, MJ | 1 |
| Tangerman, A | 1 |
| van Egmond, J | 1 |
| Dirksen, R | 1 |
| Contreras, J | 1 |
| Freymond, D | 1 |
| Dériaz, O | 1 |
| Frascarolo, P | 1 |
| Reiz, S | 1 |
| Jéquier, E | 1 |
| Martens, U | 1 |
| Krause, T | 1 |
| Steinrücke, K | 1 |
| am Esch, JS | 1 |
| Silva, HC | 1 |
| Bahia, VS | 1 |
| Oliveira, RA | 1 |
| Marchiori, PE | 1 |
| Scaff, M | 1 |
| Tsanaclis, AM | 1 |
| Romero, NB | 1 |
| Lerale, J | 1 |
| Qi, D | 1 |
| Fardeau, M | 1 |
| Froeba, G | 1 |
| Schoch, E | 1 |
| Marx, T | 1 |
| Posterino, GS | 1 |
| Yamamoto, T | 1 |
| Thamm, B | 1 |
| Aubert, M | 1 |
| Karan, SM | 1 |
| Lojeski, EW | 1 |
| Mongan, PD | 1 |
| Stojkovic, T | 1 |
| Maurage, CA | 1 |
| Moerman, A | 1 |
| Hurtevent, JF | 1 |
| Pellissier, JF | 1 |
| Vermersch, P | 1 |
| Fruen, BR | 1 |
| Mueller, CR | 1 |
| Khanna, VK | 2 |
| Meinecke, CD | 2 |
| Durbin, CG | 1 |
| Reed, SB | 1 |
| Strobel, GE | 1 |
| McComas, AJ | 1 |
| Chan, FY | 1 |
| Harrison, JE | 1 |
| McNeill, KG | 1 |
| Austin, KL | 2 |
| Peters, PL | 1 |
| Bedell, DM | 1 |
| Jones, EW | 2 |
| Clarke, IM | 1 |
| Hawkes, MJ | 1 |
| el-Hayek, R | 1 |
| Valdivia, HH | 2 |
| Coronado, R | 2 |
| Hogan, K | 2 |
| Holland, M | 4 |
| Williams, JH | 4 |
| Lee, JC | 4 |
| Orimo, S | 1 |
| Taniguchi, A | 1 |
| Ichikawa, T | 1 |
| Hiyamuta, E | 1 |
| Tamaki, M | 1 |
| Cosgrove, SB | 1 |
| Eisele, PH | 1 |
| Martucci, RW | 3 |
| Hopkinson, KC | 3 |
| McKenzie, AJ | 1 |
| Couchman, KG | 1 |
| Kawana, Y | 1 |
| Iino, M | 1 |
| Endo, M | 2 |
| Martin, JJ | 2 |
| Bossaert, LL | 2 |
| Carrier, L | 1 |
| Villaz, M | 1 |
| Dupont, Y | 1 |
| Fill, M | 1 |
| Stefani, E | 1 |
| Reiss, GK | 1 |
| Desmoulin, F | 1 |
| Martin, CF | 1 |
| Monin, G | 2 |
| Renou, JP | 1 |
| Canioni, P | 1 |
| Beech, J | 1 |
| Ashcroft, FM | 1 |
| Reyford, GH | 1 |
| Imbenotte, M | 1 |
| Cordonnier, C | 1 |
| Ward, CW | 1 |
| McGrath, CJ | 1 |
| Landis, JR | 1 |
| Bunn, JS | 1 |
| Diaz, M | 1 |
| Dupuis, BA | 3 |
| Van de Kelft, E | 1 |
| Ohnishi, ST | 3 |
| Katsuoka, M | 1 |
| Gillard, EF | 1 |
| Fujii, J | 2 |
| de Leon, S | 1 |
| Derdemezi, J | 1 |
| Duff, CL | 1 |
| Worton, RG | 3 |
| Preis, I | 1 |
| Eldar, I | 1 |
| Goldberg, G | 1 |
| Poels, PJ | 1 |
| Joosten, EM | 1 |
| Sengers, RC | 1 |
| Stadhouders, AM | 1 |
| Veerkamp, JH | 1 |
| Benders, AA | 1 |
| Payne, N | 1 |
| Gallagher, WJ | 1 |
| Sharer, S | 1 |
| Rum, U | 1 |
| Schmitz, W | 1 |
| Scholz, H | 1 |
| Seewald, MJ | 1 |
| Eichinger, HM | 1 |
| Jaffe, RS | 1 |
| Elliott, TE | 1 |
| Cardinet, GH | 1 |
| Duff, C | 1 |
| Phillips, M | 1 |
| Korneluk, RG | 1 |
| Olgin, J | 1 |
| Allen, G | 2 |
| Seestedt, R | 1 |
| Chance, B | 1 |
| Miller, KE | 1 |
| Brooks, RR | 1 |
| Bonk, KR | 1 |
| Carpenter, JF | 1 |
| Seeberger, MD | 1 |
| Rothenbühler, JM | 1 |
| Frei, F | 1 |
| Meyers, D | 1 |
| MacKenzie, AE | 1 |
| Lahey, D | 1 |
| Crossan, ML | 1 |
| Nolan, K | 1 |
| Mettler, G | 1 |
| Korneluk, R | 1 |
| Klip, A | 2 |
| Mills, GB | 1 |
| Elliott, ME | 2 |
| Bunge, G | 1 |
| Andrish, JT | 1 |
| Tetzlaff, JE | 1 |
| Cruse, RP | 1 |
| Sufit, RL | 1 |
| Kreul, JF | 1 |
| Bellay, YM | 1 |
| Helmer, P | 1 |
| Brunson, DB | 1 |
| Will, J | 1 |
| Leys, D | 1 |
| Adamantidis, M | 2 |
| Dupuis, B | 1 |
| Huggins, FJ | 3 |
| Stratton, M | 1 |
| Conner, GE | 1 |
| Conti, PA | 1 |
| Healy, JM | 1 |
| Deufel, T | 1 |
| Farrall, M | 1 |
| Johnson, K | 1 |
| Reyfort, GH | 1 |
| Litterer, LA | 2 |
| Jacobson, BA | 2 |
| Dudley, JP | 1 |
| Reynolds, R | 1 |
| Dubrow, TJ | 2 |
| Gericke, GS | 1 |
| Kalow, BI | 1 |
| Ali, N | 1 |
| Lassaline, LA | 1 |
| Lumsden, JH | 1 |
| Waring, AJ | 1 |
| Fang, SR | 1 |
| Horiuchi, K | 1 |
| Flick, JL | 1 |
| Sadanaga, KK | 1 |
| Ohnishi, T | 1 |
| Gong, QH | 1 |
| Adnet-Bonte, CA | 1 |
| Hackl, W | 2 |
| Winkler, M | 1 |
| Mauritz, W | 2 |
| Tateishi, M | 1 |
| Sumita, S | 1 |
| Watanabe, H | 1 |
| Kumeta, H | 1 |
| Narimatsu, E | 1 |
| Namiki, A | 1 |
| Salviati, G | 1 |
| Betto, R | 1 |
| Ceoldo, S | 1 |
| Della Puppa, A | 1 |
| Hopkinson, K | 1 |
| Lizzo, FH | 1 |
| Kojima, S | 1 |
| Araki, M | 1 |
| Kien, ND | 1 |
| Burket, RC | 1 |
| Hodgin, JD | 1 |
| Rempel, WE | 2 |
| Johnson, KM | 1 |
| Pegg, W | 1 |
| Ohta, T | 1 |
| Nakano, T | 1 |
| Morohoshi, Y | 1 |
| Wanikawa, K | 1 |
| Ohga, A | 1 |
| Rock, E | 1 |
| Kozak-Reiss, G | 3 |
| Reiss, G | 1 |
| Lauer, C | 1 |
| Moeller, R | 1 |
| Gascard, JP | 2 |
| Laxenaire, MC | 1 |
| Abdul-Rasool, IH | 1 |
| Lesavoy, MA | 1 |
| Collins, SP | 1 |
| White, MD | 1 |
| Hansen, U | 1 |
| Skovgaard, LT | 3 |
| Theunynck, D | 2 |
| Guévart, E | 2 |
| Heiman-Patterson, TD | 1 |
| Tahmoush, AJ | 1 |
| Lombard, TP | 1 |
| Couper, JL | 1 |
| Klein, W | 1 |
| Graf, M | 1 |
| Sluga, E | 1 |
| Larach, DR | 1 |
| Broennle, AM | 1 |
| Lennmarken, C | 1 |
| Rutberg, H | 1 |
| Henriksson, KG | 1 |
| Nagarajan, K | 1 |
| Fishbein, WN | 2 |
| Pezeshkpour, G | 1 |
| Souza, MR | 1 |
| Zapata, G | 1 |
| Suarez-Kurtz, G | 2 |
| Blomquist, S | 1 |
| Iwatsuki, N | 1 |
| Shiratori, T | 1 |
| Fudeta, H | 1 |
| Shiozawa, S | 1 |
| Amaha, K | 1 |
| Redouane-Bénichou, K | 1 |
| Biscardi, HM | 1 |
| Condon, BF | 1 |
| Scott, EA | 1 |
| Paasuke, RT | 2 |
| Fletcher, TF | 1 |
| Goettl, VM | 1 |
| Walsh, MP | 1 |
| Littmann, V | 1 |
| Krantz, P | 1 |
| Monti, M | 1 |
| Ilias, WK | 1 |
| Williams, CH | 1 |
| Fulfer, RT | 1 |
| Dozier, SE | 1 |
| Deuster, PA | 1 |
| Armbrustmacher, VW | 1 |
| Hall, GM | 1 |
| Lister, D | 1 |
| Harrison, GG | 3 |
| Moulds, RF | 4 |
| Relton, JE | 1 |
| Steward, DJ | 1 |
| Keaney, NP | 1 |
| Harriman, DG | 1 |
| Bull, AB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Freeman-Sheldon Syndrome Evaluation and Diagnosis in Clinical Settings (FSS-EDICT) I: a Case-Control, Cross-Sectional Study of Baseline and Stress Physiology Parameters[NCT01306994] | 0 participants (Actual) | Observational | 2014-03-31 | Withdrawn (stopped due to Lack of patient interest) | |||
| Implication of Patient in the Making Ready of Recommendations for the Antivitamin K's Gestion in Case of Thrombosis Embolic Venous's Illness. Randomised Study for Clinical Validation.[NCT00227097] | 300 participants | Observational | 2002-12-31 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for caffeine and Anesthesia Related Hyperthermia
| Article | Year |
|---|---|
Topics: Baths; Caffeine; Humans; In Vitro Techniques; Laboratories; Malignant Hyperthermia; Muscle Contracti | 2022 |
DNA testing for malignant hyperthermia: the reality and the dream.
Topics: Biopsy; Caffeine; Calcium Channels; Calcium Channels, L-Type; Computational Biology; Genetic Predisp | 2014 |
Clinical protocol for the management of malignant hyperthermia.
Topics: Adolescent; Adult; Caffeine; Calcium Signaling; Child; Child, Preschool; Clinical Protocols; Critica | 2017 |
Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins.
Topics: Animals; Caffeine; Calcium; Disease Models, Animal; Dogs; Female; Genotype; Humans; Hydrogen-Ion Con | 2002 |
Defective Mg2+ regulation of RyR1 as a causal factor in malignant hyperthermia.
Topics: Caffeine; Calcium; Cytosol; Halothane; Humans; Magnesium; Malignant Hyperthermia; Muscle, Skeletal; | 2007 |
[Anesthesia in malignant hyperthermia].
Topics: Adolescent; Adult; Aged; Anesthetics, Inhalation; Caffeine; Calcium Signaling; Child; Child, Prescho | 2008 |
Malignant hyperthermia.
Topics: Animals; Caffeine; Calcium; Cold Temperature; Creatine Kinase; Dantrolene; Disease Susceptibility; H | 1983 |
Malignant hyperthermia.
Topics: Adolescent; Adult; Anesthesia; Biopsy; Caffeine; Child; Child, Preschool; Clinical Protocols; Counse | 1994 |
Malignant hyperthermia.
Topics: Anesthesia; Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Dantrolene; Haloth | 1998 |
Epidemiology and inheritance of malignant hyperthermia.
Topics: Adenosine Triphosphate; Caffeine; Creatine Kinase; Female; Genetic Predisposition to Disease; Haloth | 1979 |
Preanesthetic diagnosis of malignant hyperthermia.
Topics: Adenosine Triphosphate; Caffeine; Cardiac Catheterization; Creatine Kinase; Halothane; Heart; Humans | 1979 |
Ca2+ channels and excitation-contraction coupling.
Topics: Action Potentials; Animals; Caffeine; Calcium; Calcium Channels; CHO Cells; Cricetinae; Dihydropyrid | 1991 |
Malignant hyperthermia: relation to other diseases.
Topics: Caffeine; Calcium Channels; Diagnosis, Differential; Halothane; Humans; Malignant Hyperthermia; Musc | 1990 |
[Screening tests for malignant hyperthermia susceptibility].
Topics: Animals; Caffeine; Calcium; Cholinesterases; Contracture; Creatine Kinase; Cyclic AMP; Disease Susce | 1989 |
Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.
Topics: Biopsy; Caffeine; Clinical Laboratory Techniques; Disease Susceptibility; Halothane; Humans; Maligna | 1989 |
Diagnosis of susceptibility to malignant hyperthermia in man.
Topics: Caffeine; Chemistry, Clinical; Disease Susceptibility; Halothane; Hematologic Tests; Humans; In Vitr | 1988 |
Malignant hyperpyrexia.
Topics: Adenosine Triphosphate; Anesthesia, General; Animals; Bicarbonates; Caffeine; Creatine Kinase; Glyco | 1973 |
8 trials available for caffeine and Anesthesia Related Hyperthermia
| Article | Year |
|---|---|
Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Topics: Biopsy; Caffeine; Cresols; Disease Susceptibility; Halothane; Humans; In Vitro Techniques; Malignant | 2003 |
Caffeine impairs intramuscular energy balance in patients susceptible to malignant hyperthermia.
Topics: Adult; Age Factors; Caffeine; Calcium; Calcium Signaling; Disease Susceptibility; Female; Humans; In | 2003 |
A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility.
Topics: Caffeine; Central Nervous System Stimulants; Cresols; Europe; Humans; In Vitro Techniques; Malignant | 2000 |
Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
Topics: Caffeine; DNA Mutational Analysis; Gene Frequency; Genetic Heterogeneity; Genetic Predisposition to | 2001 |
Motor unit counting and the caffeine contracture test in malignant hyperthermia.
Topics: Caffeine; Clinical Trials as Topic; Electromyography; Humans; Malignant Hyperthermia; Methods; Neuro | 1977 |
Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.
Topics: Adolescent; Adult; Aged; Biopsy; Caffeine; Child; Contracture; Disease Susceptibility; Female; Halot | 1992 |
A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Topics: Adolescent; Adult; Caffeine; Child; Child, Preschool; Disease Susceptibility; Female; Halothane; Hum | 1991 |
Identification of susceptibility to malignant hyperpyrexia.
Topics: Adolescent; Adult; Aged; Biopsy; Caffeine; Creatine Kinase; Drug Hypersensitivity; Electrocardiograp | 1974 |
358 other studies available for caffeine and Anesthesia Related Hyperthermia
| Article | Year |
|---|---|
Malignant Hyperthermia: A Killer If Ignored.
Topics: Adolescent; Caffeine; China; Halothane; Humans; Malignant Hyperthermia; Mutation | 2022 |
The effects of dantrolene in the presence or absence of ryanodine receptor type 1 variants in individuals predisposed to malignant hyperthermia.
Topics: Caffeine; Calcium; Dantrolene; Humans; Malignant Hyperthermia; Mutation; Ryanodine Receptor Calcium | 2022 |
Management of patients susceptible to malignant hyperthermia: A surgeon's perspective.
Topics: Caffeine; Child; Disease Susceptibility; Halothane; Humans; Malignant Hyperthermia; Retrospective St | 2022 |
Variants in ASPH cause exertional heat illness and are associated with malignant hyperthermia susceptibility.
Topics: Animals; Caffeine; Calcium-Binding Proteins; Heat Stress Disorders; Humans; Malignant Hyperthermia; | 2022 |
Gene Panel Sequencing Identifies a Novel
Topics: Adolescent; Caffeine; Calcium; Dantrolene; Humans; Isoflurane; Male; Malignant Hyperthermia; Ryanodi | 2022 |
Distinct pathophysiological characteristics in developing muscle from patients susceptible to malignant hyperthermia.
Topics: Caffeine; Calcium; Disease Susceptibility; Halothane; Humans; Malignant Hyperthermia; Muscle Contrac | 2023 |
What is malignant hyperthermia susceptibility?
Topics: Anesthesia; Biopsy; Caffeine; Halothane; Humans; Malignant Hyperthermia | 2023 |
A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.
Topics: Adult; Anesthetics, Inhalation; Caffeine; Female; Genotype; Halothane; Humans; Malignant Hyperthermi | 2020 |
Effects of Remimazolam and Propofol on Ca
Topics: Anesthetics; Benzodiazepines; Caffeine; Calcium; HEK293 Cells; Humans; Malignant Hyperthermia; Mutat | 2021 |
Assessing the pathogenicity of RYR1 variants in malignant hyperthermia.
Topics: Caffeine; Calcium; Cloning, Molecular; Family; Genetic Predisposition to Disease; Genetic Variation; | 2017 |
Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia.
Topics: Animals; Caffeine; Calcium-Binding Proteins; Calsequestrin; Electric Stimulation; Gene Expression Re | 2017 |
Skeletal Muscle Metabolic Dysfunction in Patients With Malignant Hyperthermia Susceptibility.
Topics: Adult; Anesthetics; Anthropometry; Caffeine; Case-Control Studies; Disease Susceptibility; Exercise | 2017 |
Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia.
Topics: Animals; Caffeine; Calcium; Child; Cresols; Genetic Predisposition to Disease; HEK293 Cells; Humans; | 2018 |
Malignant Hyperthermia: From the OR to the Sidelines.
Topics: Anesthesia; Animals; Caffeine; Dantrolene; Humans; Malignant Hyperthermia; Muscle Contraction; Ryano | 2018 |
Microdialysis and ultrasound elastography for monitoring of localized muscular reaction after pharmacological stimulation in rats.
Topics: Animals; Caffeine; Elasticity Imaging Techniques; Halothane; Malignant Hyperthermia; Microdialysis; | 2018 |
Ultrasound Elastography for Rapid, Real-time Detection of Localized Muscular Reaction in Malignant Hyperthermia-susceptible Pigs.
Topics: Anesthetics, Inhalation; Animals; Caffeine; Central Nervous System Stimulants; Disease Models, Anima | 2018 |
Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1.
Topics: Anesthetics, Inhalation; Animals; Caffeine; Calcium; Calcium Signaling; Dose-Response Relationship, | 2018 |
Abnormal calcium signalling and the caffeine-halothane contracture test.
Topics: Adult; Anesthetics, Inhalation; Caffeine; Calcium; Cells, Cultured; Disease Susceptibility; Dose-Res | 2019 |
Understanding malignant hyperthermia: each move forward opens our eyes to the distance left to travel.
Topics: Caffeine; Calcium; Contracture; Halothane; Humans; Malignant Hyperthermia | 2019 |
In vitro muscle contracture investigations on the malignant hyperthermia like episodes in myotonia congenita.
Topics: Anesthetics, Inhalation; Animals; Caffeine; Calcium; Central Nervous System Stimulants; Dose-Respons | 2013 |
Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.
Topics: Adolescent; Adult; Aged; Anesthetics; Caffeine; Canada; Child; Child, Preschool; Dantrolene; Female; | 2014 |
Analysis of histomorphology in malignant hyperthermia-susceptible patients.
Topics: Adult; Caffeine; Female; Follow-Up Studies; Genetic Predisposition to Disease; Genotype; Halothane; | 2013 |
[Malignant hyperthermia: multifactorial events leading to a crisis].
Topics: Accidents, Traffic; Algorithms; Bicycling; Biopsy; Caffeine; Central Nervous System Stimulants; Gene | 2013 |
Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia.
Topics: Anesthesia, General; Anesthetics, General; Animals; Biopsy; Caffeine; Central Nervous System Stimula | 2014 |
Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility.
Topics: Blotting, Western; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Cresols; D | 2014 |
Effect of caffeine on intrinsic mechanical properties of normal and malignant hyperthermia-susceptible muscle.
Topics: Caffeine; Cross-Sectional Studies; Dose-Response Relationship, Drug; Electric Stimulation; Female; H | 2015 |
Malignant hyperthermia testing in probands without adverse anesthetic reaction.
Topics: Adolescent; Adult; Aged; Anesthetics, Inhalation; Caffeine; Dantrolene; Drug-Related Side Effects an | 2015 |
Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
Topics: Adult; Anesthetics, Inhalation; Caffeine; Contracture; Disease Susceptibility; Female; Halothane; He | 2015 |
Several Ryanodine Receptor Type 1 Gene Mutations of p.Arg2508 Are Potential Sources of Malignant Hyperthermia.
Topics: Animals; Arginine; Caffeine; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Malignant Hyper | 2015 |
Cystathionine β-synthase-derived hydrogen sulfide is involved in human malignant hyperthermia.
Topics: Biopsy; Caffeine; Case-Control Studies; Cystathionine beta-Synthase; Dose-Response Relationship, Dru | 2016 |
Functional characterization of the RYR1 mutation p.Arg4737Trp associated with susceptibility to malignant hyperthermia.
Topics: Anesthetics; Arginine; B-Lymphocytes; Caffeine; Cell Line, Transformed; Cresols; Family Health; Fema | 2016 |
Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals.
Topics: Adult; B-Lymphocytes; Biomarkers; Caffeine; Calcium; Cell Line, Transformed; Cresols; Disease Suscep | 2016 |
[In-vivo diagnosis of malignant hyperthermia susceptibility: a microdialysis study].
Topics: Adolescent; Adult; Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Creatine; D | 2008 |
An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
Topics: Adult; Biopsy; Caffeine; Case-Control Studies; Disease Susceptibility; Female; Halothane; Humans; La | 2008 |
Novel ryanodine receptor mutation that may cause malignant hyperthermia.
Topics: Amino Acid Substitution; Anesthetics, Inhalation; Austria; Caffeine; Calcium; Cells, Cultured; Centr | 2008 |
Eccentric contractions do not induce rhabdomyolysis in malignant hyperthermia susceptible mice.
Topics: Animals; Caffeine; Dose-Response Relationship, Drug; Electric Stimulation; Glutathione; Isometric Co | 2008 |
Increasing the number of diagnostic mutations in malignant hyperthermia.
Topics: Caffeine; Calcium; Cell Line, Transformed; Cresols; DNA Mutational Analysis; Dose-Response Relations | 2009 |
You're "hot" from pumping iron?
Topics: Anesthesia; Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Creatine; Dietary | 2009 |
Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice.
Topics: Anesthetics; Animals; Caffeine; Calcium; Calcium-Binding Proteins; Calsequestrin; Central Nervous Sy | 2009 |
Effects of propofol on calcium homeostasis in human skeletal muscle.
Topics: Adolescent; Adult; Aged; Anesthetics, Intravenous; Caffeine; Calcium; Child; Child, Preschool; Dose- | 2009 |
Genetic variation in RYR1 and malignant hyperthermia phenotypes.
Topics: Anesthetics, Inhalation; Caffeine; Creatine Kinase; DNA Mutational Analysis; DNA, Complementary; Fem | 2009 |
Functional analysis of ryanodine receptor type 1 p.R2508C mutation in exon 47.
Topics: Adolescent; Anesthesia, General; Animals; Caffeine; Calcium; Cell Line; DNA; DNA, Complementary; Dos | 2009 |
Malignant hyperthermia susceptibility in a patient with mitochondrial disorder.
Topics: Abnormalities, Multiple; Aged; Anesthesia; Anesthetics, Inhalation; Caffeine; Halothane; Humans; Mal | 2009 |
Intramuscular injection of malignant hyperthermia trigger agents induces hypermetabolism in susceptible and nonsusceptible individuals.
Topics: Adolescent; Adult; Aged; Caffeine; Carbon Dioxide; Female; Halothane; Humans; Injections, Intramuscu | 2010 |
The role of CACNA1S in predisposition to malignant hyperthermia.
Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Caffeine; Calcium Channels; Calcium Channels, L-Type; | 2009 |
Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene.
Topics: Brazil; Caffeine; Contracture; Family; Female; Genetic Testing; Halothane; Humans; Male; Malignant H | 2009 |
Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
Topics: Adolescent; Adult; Aged; Anesthetics, Inhalation; Biopsy; Caffeine; Child; Child, Preschool; Contrac | 2010 |
Clinical features and diagnosis for Chinese cases with malignant hyperthermia: a case cluster from 2005 to 2007.
Topics: Adolescent; Adult; Caffeine; Child; China; Female; Halothane; Humans; In Vitro Techniques; Male; Mal | 2010 |
Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit.
Topics: Action Potentials; Amino Acid Sequence; Animals; Base Sequence; Caffeine; Calcium Channels; Calcium | 2010 |
Analysis of human cultured myotubes responses mediated by ryanodine receptor 1.
Topics: Adolescent; Adult; Aged; Caffeine; Calcium; Cells, Cultured; Child; Child, Preschool; Cresols; Dose- | 2011 |
Sevoflurane as a potential replacement for halothane in diagnostic testing for malignant hyperthermia susceptibility: results of a preliminary study.
Topics: Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Disease Susceptibility; Dose-R | 2011 |
Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families.
Topics: Caffeine; Calcium; Child; Female; Humans; Infant; Male; Malignant Hyperthermia; Mutation; Ryanodine | 2011 |
Mutated p.4894 RyR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1).
Topics: Animals; Caffeine; Calcium; Genetic Variation; HEK293 Cells; Humans; Malignant Hyperthermia; Muscle | 2011 |
Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families.
Topics: Amino Acid Substitution; Anesthesia, General; Anesthetics, Inhalation; Caffeine; Calcium; Cells, Cul | 2012 |
3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.
Topics: Caffeine; Calcium; Calcium Channel Agonists; Catechols; Cells, Cultured; Dose-Response Relationship, | 2012 |
Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.
Topics: Analysis of Variance; Anesthetics; Body Temperature; Caffeine; Calcium; Caveolin 1; DNA, Complementa | 2012 |
A family with discordance between malignant hyperthermia susceptibility and rippling muscle disease.
Topics: Anesthesia; Anesthesia, General; Anesthetics, Inhalation; Caffeine; Caveolin 3; Creatine Kinase; Fam | 2013 |
RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Topics: Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Exons; Female; Halothane; Huma | 2002 |
Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
Topics: Adolescent; Adult; Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Child; Chil | 2002 |
Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation.
Topics: Amino Acid Substitution; Caffeine; Calcium; Cresols; Female; Humans; Male; Malignant Hyperthermia; M | 2002 |
Effects of Mg(2+) and SR luminal Ca(2+) on caffeine-induced Ca(2+) release in skeletal muscle from humans susceptible to malignant hyperthermia.
Topics: Caffeine; Calcium; Disease Susceptibility; Humans; Magnesium; Malignant Hyperthermia; Muscle, Skelet | 2002 |
Reproducibility of in vitro contracture test results in patients tested for malignant hyperthermia susceptibility.
Topics: Adult; Anesthetics, Inhalation; Biopsy; Caffeine; Disease Susceptibility; Female; Halothane; Humans; | 2002 |
"Noninvasive" testing for malignant hyperthermia susceptibility.
Topics: Caffeine; Calcium; Cresols; Disease Susceptibility; Halothane; Humans; Malignant Hyperthermia; Muscl | 2002 |
Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes.
Topics: Adolescent; Adult; B-Lymphocytes; Caffeine; Calcium; Child; Cresols; Disease Susceptibility; Halotha | 2002 |
Extending the skeletal muscle viability period in the malignant hyperthermia test.
Topics: Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Electric Stimulation; Halothan | 2003 |
Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling.
Topics: Animals; Caffeine; Calcium; Cell Membrane; Central Nervous System Stimulants; Collagen; Cresols; DNA | 2003 |
Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript.
Topics: Amino Acid Substitution; Anesthetics, Inhalation; Caffeine; Cell Line; DNA, Complementary; Halothane | 2003 |
Regional lactate and carbon dioxide concentrations in a metabolic test for malignant hyperthermia.
Topics: Animals; Caffeine; Carbon Dioxide; Humans; Injections, Intramuscular; Lactates; Malignant Hypertherm | 2003 |
Malignant hyperthermia.
Topics: Anesthesia, General; Anesthetics, Inhalation; Caffeine; Calcium; Central Nervous System Stimulants; | 2003 |
Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.
Topics: Adult; Aged; Caffeine; Calcium; Child; Child, Preschool; Cresols; Female; Genetic Predisposition to | 2003 |
Caffeine sensitivity of native RyR channels from normal and malignant hyperthermic pigs: effects of a DHPR II-III loop peptide.
Topics: Animals; Caffeine; Calcium; Ion Channel Gating; Malignant Hyperthermia; Muscle Contraction; Peptide | 2004 |
A new mutation in the skeletal ryanodine receptor gene (RYR1) is potentially causative of malignant hyperthermia, central core disease, and severe skeletal malformation.
Topics: Adolescent; Base Sequence; Caffeine; DNA; DNA Mutational Analysis; Dysostoses; Family Health; Female | 2004 |
Genetic testing for malignant hyperthermia in North America.
Topics: Anesthetics, Inhalation; Caffeine; Genetic Testing; Halothane; Humans; Malignant Hyperthermia; Muscl | 2004 |
Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthetics, Inhalation; Biopsy; Caffeine; Central Nervo | 2004 |
[Delayed onset of malignant hyperthermia crisis during a living donor liver transplantation caused by sevoflurane].
Topics: Adult; Anesthesia, Inhalation; Anesthetics, Inhalation; Blood Gas Analysis; Caffeine; Central Nervou | 2004 |
Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling.
Topics: Animals; Caffeine; Calcium; Calcium Channels, L-Type; Cells, Cultured; Central Nervous System Stimul | 2004 |
Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
Topics: Adolescent; Adult; Aged; Anesthetics; Biopsy; Caffeine; Calcium; Cells, Cultured; Central Nervous Sy | 2004 |
4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility.
Topics: Caffeine; Calcium; Calibration; Cells, Cultured; Central Nervous System Stimulants; Cresols; DNA Mut | 2004 |
Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease.
Topics: Caffeine; Calcium; Cells, Cultured; Cycloheximide; Cyclosporine; Disease Susceptibility; Homeostasis | 2004 |
Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
Topics: Anesthetics, Inhalation; Caffeine; DNA; Halothane; Humans; In Vitro Techniques; Malignant Hypertherm | 2004 |
Enhanced response to caffeine and 4-chloro-m-cresol in malignant hyperthermia-susceptible muscle is related in part to chronically elevated resting [Ca2+]i.
Topics: Animals; Animals, Newborn; Caffeine; Calcium; Central Nervous System Stimulants; Chelating Agents; C | 2005 |
Mg2+ dependence of halothane-induced Ca2+ release from the sarcoplasmic reticulum in skeletal muscle from humans susceptible to malignant hyperthermia.
Topics: Anesthetics, Inhalation; Caffeine; Calcium; Central Nervous System Stimulants; Cytosol; Halothane; H | 2004 |
Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations.
Topics: Aequorin; Animals; Animals, Newborn; Blotting, Western; Caffeine; Calcium; Cell Line; Cytosol; Endop | 2005 |
Malignant hyperthermia: update on susceptibility testing.
Topics: Algorithms; B-Lymphocytes; Biopsy; Caffeine; Disease Susceptibility; DNA Mutational Analysis; Haloth | 2005 |
Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.
Topics: Anesthesia; Anesthetics; Animals; Caffeine; Calcium; Disease Models, Animal; Hot Temperature; Isoflu | 2006 |
Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Topics: Anesthesia, General; Anesthetics, Dissociative; Anesthetics, Inhalation; Anesthetics, Intravenous; A | 2006 |
The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs.
Topics: Anesthetics, Inhalation; Animals; Caffeine; Carbon Dioxide; Disease Susceptibility; Dose-Response Re | 2006 |
Validity and new malignant hyperthermia diagnostic procedures.
Topics: Caffeine; Halothane; Humans; Malignant Hyperthermia; Muscle Contraction; Reproducibility of Results; | 2006 |
Characterization of ryanodine receptor-mediated calcium release in human B cells: relevance to diagnostic testing for malignant hyperthermia.
Topics: Animals; B-Lymphocytes; Caffeine; Calcium; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Cells | 2006 |
Malignant hyperthermia in China.
Topics: Anesthesia, General; Caffeine; China; Halothane; Humans; In Vitro Techniques; Male; Malignant Hypert | 2006 |
Postulated role of interdomain interaction between regions 1 and 2 within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermia.
Topics: Adenosine Triphosphate; Amino Acid Motifs; Animals; Caffeine; Calcium; Magnesium; Malignant Hyperthe | 2007 |
Male preponderance of patients testing positive for malignant hyperthermia susceptibility.
Topics: Caffeine; Family; Female; Genetic Predisposition to Disease; Halothane; Humans; Male; Malignant Hype | 2007 |
Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Topics: Animals; Caffeine; Disease Susceptibility; Halothane; Kinetics; Lactates; Malignant Hyperthermia; Mi | 2008 |
Fulminant malignant hyperthermia.
Topics: Adult; Anesthetics, General; Caffeine; Halothane; Humans; Male; Malignant Hyperthermia; Muscle Contr | 2008 |
[Application of caffeine-halothane contracture test in the diagnosis of malignant hyperthermia].
Topics: Anesthetics, Inhalation; Caffeine; Creatine Kinase; Enzyme-Linked Immunosorbent Assay; Halothane; Hu | 2008 |
A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Caffeine; Halothane; Humans; Male; Malignant Hyperthe | 1982 |
Effects of midazolam on directly stimulated muscle biopsies from control and malignant hyperthermia positive patients.
Topics: Anti-Anxiety Agents; Benzodiazepines; Caffeine; Halothane; Humans; In Vitro Techniques; Malignant Hy | 1984 |
Adenylate kinase deficiency and malignant hyperthermia.
Topics: Adenylate Kinase; Adult; Biopsy; Caffeine; Child; Female; Humans; Male; Malignant Hyperthermia; Musc | 1981 |
Phosphorylase ratio and susceptibility to malignant hyperthermia.
Topics: Adolescent; Adult; Caffeine; Clinical Enzyme Tests; Female; Humans; In Vitro Techniques; Male; Malig | 1983 |
Prolonged electromechanical coupling time intervals in skeletal muscle of pigs susceptible to malignant hyperthermia.
Topics: Animals; Caffeine; Disease Models, Animal; Electric Stimulation; Halothane; Kinetics; Malignant Hype | 1983 |
Dantrolene does not block calcium pulse-induced calcium release from a putative calcium channel in sarcoplasmic reticulum from malignant hyperthermia and normal pig muscle.
Topics: Animals; Caffeine; Calcium; Dantrolene; Halothane; Ion Channels; Malignant Hyperthermia; Muscle Cont | 1984 |
Investigation of malignant hyperthermia in Denmark and Sweden.
Topics: Adolescent; Adult; Aged; Biopsy; Caffeine; Child; Creatine Kinase; Disease Susceptibility; Female; G | 1984 |
A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
Topics: Biopsy; Caffeine; Disease Susceptibility; Genetic Testing; Halothane; Humans; In Vitro Techniques; M | 1984 |
Electrodiagnostic tests in the detection of malignant hyperthermia.
Topics: Adolescent; Adult; Caffeine; Electric Stimulation; Electromyography; Evoked Potentials; Female; Halo | 1984 |
Malignant hyperthermia and related neuromuscular diseases: caffeine contracture of the skinned muscle fibers.
Topics: Adolescent; Adult; Aged; Caffeine; Child; Humans; In Vitro Techniques; Malignant Hyperthermia; Middl | 1983 |
Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.
Topics: Animals; Caffeine; Calcium; Dantrolene; Dose-Response Relationship, Drug; Drug Interactions; Humans; | 1984 |
Halothane-succinylcholine induced masseter spasm: indicative of malignant hyperthermia susceptibility?
Topics: Caffeine; Child; Child, Preschool; Creatine Kinase; Female; Halothane; Humans; Male; Malignant Hyper | 1984 |
In vitro contracture tests for susceptibility to malignant hyperthermia.
Topics: Caffeine; Disease Susceptibility; Drug Interactions; Halothane; Humans; Malignant Hyperthermia; Musc | 1983 |
Halothane-induced ATP depletion in platelets from patients susceptible to malignant hyperthermia and from controls.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Adolescent; Adult; Blood Pla | 1983 |
Spectrum of susceptibility to malignant hyperthermia--diagnostic dilemma.
Topics: Animals; Body Temperature; Caffeine; Disease Susceptibility; Halothane; Humans; In Vitro Techniques; | 1983 |
Is theophylline, aminophylline, or caffeine (methylxanthines) contraindicated in malignant hyperthermia susceptible patients?
Topics: Adolescent; Adult; Aminophylline; Caffeine; Child; Halothane; Humans; In Vitro Techniques; Male; Mal | 1983 |
The control of muscle contracture by the action of dantrolene on the sarcolemma.
Topics: Animals; Caffeine; Dantrolene; Diaphragm; Dinitrophenols; Dose-Response Relationship, Drug; Halothan | 1983 |
Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia.
Topics: Animals; Caffeine; Calcium; Disease Susceptibility; Malignant Hyperthermia; Muscle Contraction; Musc | 1983 |
Screening for malignant hyperthermia susceptibility.
Topics: Caffeine; Dantrolene; Halothane; Humans; Malignant Hyperthermia; Mass Screening; Muscle Contraction; | 1980 |
[Malignant hyperthermia-results of familial investigations in Austria (author's transl)].
Topics: Adenosine Triphosphate; Austria; Caffeine; Calcium; Chlorpromazine; Creatine Kinase; Halothane; Huma | 1981 |
Mechanical properties of normal and malignant hyperthemia susceptible porcine muscle: effects of halothane and other drugs.
Topics: Animals; Anura; Caffeine; Drug Interactions; Epinephrine; Halothane; In Vitro Techniques; Male; Mali | 1980 |
Masseter spasm induced by succinylcholine in children: contracture testing for malignant hyperthermia: report of six cases.
Topics: Anesthesia; Caffeine; Child; Child, Preschool; Halothane; Humans; Male; Malignant Hyperthermia; Mass | 1982 |
Malignant hyperthermia: a disease of specific myofiber type?
Topics: Animals; Caffeine; Kinetics; Malignant Hyperthermia; Muscle Contraction; Swine | 1982 |
The in-vitro caffeine contracture test: influence of the muscle histochemical profile on test results.
Topics: Animals; Caffeine; Halothane; Histocytochemistry; Male; Malignant Hyperthermia; Muscle Contraction; | 1982 |
Pharmacological in-vitro studies in malignant hyperthermia in childhood.
Topics: Adolescent; Biopsy; Caffeine; Child; Child, Preschool; Dose-Response Relationship, Drug; Halothane; | 1982 |
Comparison of the caffeine skinned fibre tension (CSFT) test with the caffeine-halothane contracture (CHC) test in the diagnosis of malignant hyperthermia.
Topics: Anesthesia; Caffeine; Calcium; Halothane; Humans; In Vitro Techniques; Malignant Hyperthermia; Muscl | 1982 |
Human malignant hyperthermia: awake episodes and correction by dantrolene.
Topics: Adenosine Triphosphate; Adult; Caffeine; Dantrolene; Fatigue; Female; Halothane; Humans; In Vitro Te | 1980 |
Calcium content and contracture in isolated muscle of malignant hyperthermia in pigs.
Topics: Animals; Caffeine; Calcium; Halothane; In Vitro Techniques; Magnesium; Malignant Hyperthermia; Muscl | 1981 |
Temperature dependence of muscle function in malignant hyperpyrexia-susceptible swine.
Topics: Animals; Caffeine; Halothane; In Vitro Techniques; Malignant Hyperthermia; Muscle Contraction; Potas | 1981 |
Effect of temperature, time and fascicle size on the caffeine contracture test.
Topics: Caffeine; Dose-Response Relationship, Drug; Halothane; Humans; In Vitro Techniques; Malignant Hypert | 1980 |
Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle.
Topics: Anesthesia, Inhalation; Anesthetics; Caffeine; Dose-Response Relationship, Drug; Humans; In Vitro Te | 1980 |
Site of the muscle cell abnormality in swine susceptible to malignant hyperpyrexia.
Topics: Acetylcholine; Animals; Caffeine; Dantrolene; Halothane; In Vitro Techniques; Malignant Hyperthermia | 1980 |
Dantrolene and caffeine contracture test.
Topics: Adult; Caffeine; Dantrolene; Female; Humans; Malignant Hyperthermia; Muscle Contraction | 1980 |
Dantrolene and caffeine contracture test.
Topics: Adult; Caffeine; Dantrolene; Female; Humans; Malignant Hyperthermia; Muscle Contraction | 1980 |
Increased myophosphorylase a in malignant hyperthermia.
Topics: Adenosine Monophosphate; Adolescent; Caffeine; Child, Preschool; Enzyme Activation; Female; Humans; | 1980 |
Malignant hyperthermia susceptibility. A light and electron microscopic study of endomyocardial biopsy specimens from nine patients.
Topics: Adolescent; Adult; Caffeine; Cardiomyopathies; Female; Halothane; Heart Diseases; Humans; Male; Mali | 1980 |
The point mutation Arg615-->Cys in the Ca2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia.
Topics: Amino Acid Sequence; Animals; Arginine; Blotting, Western; Caffeine; Calcium; Calcium Channels; Cell | 1994 |
Genotype and phenotype relationships for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia.
Topics: Anesthetics, Inhalation; Caffeine; Calcium Channels; Central Nervous System Stimulants; DNA Mutation | 1995 |
C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
Topics: Adolescent; Adult; Aged; Base Sequence; Caffeine; Calcium Channels; Child; Child, Preschool; Chromos | 1995 |
The effect of calcium channel antagonists and BAY K 8644 on calcium fluxes of malignant hyperpyrexia-susceptible muscle.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1993 |
Abnormal action potential responses to halothane in heart muscle isolated from malignant hyperthermia-susceptible pigs.
Topics: Action Potentials; Animals; Caffeine; Dose-Response Relationship, Drug; Electric Stimulation; Haloth | 1995 |
Malignant hyperthermia in a patient with Becker muscular dystrophy: dystrophin analysis and caffeine contracture study.
Topics: Adolescent; Anesthesia, General; Blotting, Southern; Blotting, Western; Caffeine; Cell Membrane; Dys | 1995 |
Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
Topics: Adult; Biopsy; Caffeine; Cocaine; Contracture; Disease Susceptibility; Female; Halothane; Humans; Ma | 1995 |
[Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome].
Topics: Adolescent; Adult; Aged; Anesthesia, General; Caffeine; Contracture; Creatine Kinase; Dantrolene; Di | 1994 |
Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia Recovery Period; Anesthesia, Conduction; Anes | 1995 |
Malignant hyperthermia during sevoflurane administration.
Topics: Adult; Anesthetics; Caffeine; Disease Susceptibility; Ethers; Female; Halothane; Humans; Malignant H | 1995 |
Exercise induced hyperthermia in a racing greyhound.
Topics: Animals; Caffeine; Dog Diseases; Dogs; Exercise Test; Halothane; In Vitro Techniques; Male; Malignan | 1994 |
Caffeine stimulation of malignant hyperthermia-susceptible sarcoplasmic reticulum Ca2+ release channel.
Topics: Animals; Caffeine; Calcium Channels; Disease Susceptibility; Electrophysiology; Hydrogen-Ion Concent | 1994 |
Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.
Topics: Adolescent; Biopsy; Caffeine; Child; Child, Preschool; Creatine Kinase; Disease Susceptibility; Fema | 1994 |
Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
Topics: Adult; Biopsy; Caffeine; Child; Disease Susceptibility; Family; Fatal Outcome; Female; Halothane; Hu | 1994 |
Viability criterion of muscle bundles used in the in vitro contracture test in patients with neuromuscular diseases.
Topics: Caffeine; Disease Susceptibility; Halothane; Humans; In Vitro Techniques; Malignant Hyperthermia; Me | 1994 |
Malignant hyperthermia--diagnostic dilemma: false-negative contracture responses with halothane and caffeine alone.
Topics: Caffeine; Child; False Negative Reactions; Female; Halothane; Humans; Male; Malignant Hyperthermia | 1994 |
[Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Topics: Adult; Caffeine; Child; Child, Preschool; Disease Susceptibility; Halothane; Humans; In Vitro Techni | 1993 |
[High purity ryanodine for in vitro diagnosis of malignant hyperthermia].
Topics: Adolescent; Adult; Caffeine; Child; Culture Techniques; Dose-Response Relationship, Drug; Female; Ha | 1993 |
Combined caffeine-halothane test for malignant hyperthermia.
Topics: Caffeine; Halothane; Humans; Malignant Hyperthermia; Muscle Contraction | 1993 |
False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia.
Topics: Adolescent; Adult; Biopsy; Caffeine; Child, Preschool; False Negative Reactions; Female; Halothane; | 1993 |
Fiber-type caffeine sensitivities in skinned muscle fibers from humans susceptible to malignant hyperthermia.
Topics: Caffeine; Disease Susceptibility; Humans; In Vitro Techniques; Malignant Hyperthermia; Muscles | 1993 |
[In vitro caffeine test on skeletal muscle samples from swine].
Topics: Animals; Caffeine; Malignant Hyperthermia; Muscle Contraction; Muscles; Reproducibility of Results; | 1993 |
Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Aged; Biopsy; Caffeine; Disease Susceptibility; Female; Halothane; Humans; Magnet | 1993 |
Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
Topics: Caffeine; Disease Susceptibility; Dose-Response Relationship, Drug; Halothane; Humans; In Vitro Tech | 1993 |
On the nature of the link between malignant hyperthermia and exertional heatstroke.
Topics: Animals; Body Temperature Regulation; Caffeine; Calcium Channels; Disease Models, Animal; Disease Su | 1995 |
Malignant hyperthermia in the otology patient: the UCLA experience.
Topics: Administration, Inhalation; Adult; Anesthetics; Caffeine; Child; Child, Preschool; Dantrolene; Femal | 1994 |
Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Topics: Anesthetics, Inhalation; Caffeine; Disease Susceptibility; Female; Halothane; Heterozygote; Humans; | 1996 |
Caffeine-halothane accuracy in MH testing.
Topics: Caffeine; Drug Stability; Drug Storage; Halothane; Humans; Malignant Hyperthermia | 1995 |
Chlorocresol, an additive to commercial succinylcholine, induces contracture of human malignant hyperthermia-susceptible muscles via activation of the ryanodine receptor Ca2+ channel.
Topics: Animals; Caffeine; Calcium; Calcium Channels; Cresols; Dose-Response Relationship, Drug; Humans; In | 1996 |
4-Chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle.
Topics: Animals; Caffeine; Calcium; Cresols; Malignant Hyperthermia; Muscle, Skeletal; Protein Binding; Ryan | 1996 |
Malignant hyperthermia suggestive hypermetabolic syndrome at emergence from anesthesia.
Topics: Caffeine; Child; Creatine Kinase; Diagnosis, Differential; Female; Halothane; Humans; Malignant Hype | 1995 |
Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Topics: Adolescent; Adult; Aged; Anesthetics, Inhalation; Caffeine; Child; Halothane; Humans; In Vitro Techn | 1996 |
Malignant hyperthermia.
Topics: Anesthesia, General; Caffeine; Counseling; Disease Susceptibility; Halothane; Humans; Malignant Hype | 1996 |
[Definition of a diagnostic score of malignant hyperthermia using P-31 magnetic resonance spectroscopy].
Topics: Caffeine; Contracture; Disease Susceptibility; Halothane; Humans; Magnetic Resonance Spectroscopy; M | 1996 |
Reduced Mg2+ inhibition of Ca2+ release in muscle fibers of pigs susceptible to malignant hyperthermia.
Topics: Animals; Caffeine; Calcium; Calcium Channel Blockers; Dantrolene; Genetic Predisposition to Disease; | 1997 |
An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
Topics: Adolescent; Adult; Aged; Biopsy; Caffeine; Child; Contracture; Disease Susceptibility; Halothane; Hu | 1997 |
Rapid, simple and sensitive microassay for skeletal muscle homogenates in the functional assessment of the Ca-release channel of sarcoplasmic reticulum: application to diagnosis of susceptibility to malignant hyperthermia.
Topics: Animals; Caffeine; Calcium; Calcium Channels; Calcium-Transporting ATPases; Disease Models, Animal; | 1997 |
Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.
Topics: Adolescent; Adult; Anesthetics, Inhalation; Biopsy, Needle; Caffeine; Child; Child, Preschool; Clini | 1997 |
Recombination between the postulated CCD/MHE/MHS locus and RYR1 gene markers.
Topics: Alleles; Caffeine; Calcium Channels; Child, Preschool; Chromosomes, Human, Pair 19; Female; Genetic | 1996 |
Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
Topics: Adolescent; Adult; Aged; Anesthetics, Inhalation; Caffeine; Cresols; Disease Susceptibility; Dose-Re | 1997 |
Clinical reassessment of malignant hyperthermia in Abitibi-Témiscamingue.
Topics: Adolescent; Adult; Caffeine; Child; Disease Susceptibility; Family Characteristics; Female; Halothan | 1997 |
Malignant hyperthermia susceptibility, an autosomal dominant disorder?
Topics: Adolescent; Adult; Caffeine; Calcium Channels; Child; Child, Preschool; Female; Genes, Dominant; Gen | 1997 |
[Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
Topics: Adolescent; Adult; Caffeine; Cresols; Disease Susceptibility; Halothane; Humans; In Vitro Techniques | 1997 |
Dystrophin deficient mdx muscle is not prone to MH susceptibility: an in vitro study.
Topics: Anesthetics, Inhalation; Animals; Caffeine; Disease Susceptibility; Dystrophin; Halothane; Male; Mal | 1997 |
In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia; Biopsy; Caffeine; Child; Child, Preschool; F | 1997 |
4-Chloro-m-cresol test--a possible supplementary test for diagnosis of malignant hyperthermia susceptibility.
Topics: Biopsy; Caffeine; Cresols; Disease Susceptibility; Dose-Response Relationship, Drug; Halothane; Huma | 1997 |
Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.
Topics: Animals; Caffeine; Calcium; Cell Line; DNA, Complementary; Halothane; Humans; Malignant Hyperthermia | 1997 |
Reduced inhibitory effect of Mg2+ on ryanodine receptor-Ca2+ release channels in malignant hyperthermia.
Topics: Animals; Binding Sites; Biophysical Phenomena; Biophysics; Caffeine; Calcium; Halothane; Humans; In | 1997 |
The Israeli Diagnostic Center for Malignant Hyperthermia: 7-years' accumulated experience.
Topics: Academies and Institutes; Adult; Aged; Biopsy; Caffeine; Child; Electromyography; Female; Genetic Pr | 1997 |
Muscle biopsy for malignant hyperthermia screening in children.
Topics: Adolescent; Anesthetics, Inhalation; Biopsy; Caffeine; Central Nervous System Stimulants; Child; Dis | 1997 |
Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation.
Topics: Anesthesia; Caffeine; Denmark; Female; Genetic Predisposition to Disease; Halothane; Humans; Male; M | 1997 |
The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
Topics: Adult; Caffeine; Contracture; Female; Halothane; Humans; In Vitro Techniques; Male; Malignant Hypert | 1998 |
Rhabdomyolysis after infection and taking a cold medicine in a patient who was susceptible to malignant hyperthermia.
Topics: Adult; Caffeine; Chlorpheniramine; Common Cold; Dantrolene; Halothane; Humans; In Vitro Techniques; | 1998 |
Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia.
Topics: Adult; Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Disease Susceptibility; | 1998 |
Measurement of resting cytosolic Ca2+ concentrations and Ca2+ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca2+ release channels.
Topics: Animals; Caffeine; Calcium; Calcium Channels; Calcium-Transporting ATPases; Carbachol; Cell Line; Cy | 1999 |
Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families.
Topics: Caffeine; DNA Primers; Female; Halothane; Humans; Italy; Male; Malignant Hyperthermia; Muscles; Myop | 1999 |
Comparison of European and North American malignant hyperthermia diagnostic protocol outcomes for use in genetic studies.
Topics: Caffeine; Clinical Laboratory Techniques; Europe; Female; Humans; Male; Malignant Hyperthermia; Musc | 1999 |
[Malignant hyperthermia: difficulty in diagnosing susceptibility in Spain].
Topics: Anesthetics, Inhalation; Caffeine; Europe; Genetic Predisposition to Disease; Halothane; Humans; Inf | 1999 |
ATX II, a sodium channel toxin, sensitizes skeletal muscle to halothane, caffeine, and ryanodine.
Topics: Animals; Caffeine; Cnidarian Venoms; Female; Halothane; Humans; Male; Malignant Hyperthermia; Muscle | 1999 |
Comparison between the European and North American protocols for diagnosis of malignant hyperthermia susceptibility in humans.
Topics: Caffeine; Halothane; Humans; Malignant Hyperthermia; Muscle Contraction; Sensitivity and Specificity | 1999 |
Effects of halothane on mechanical response of skeletal muscle from malignant hyperthermia susceptible patients.
Topics: Anesthetics, Inhalation; Biopsy; Caffeine; Disease Susceptibility; Halothane; Humans; In Vitro Techn | 1998 |
Abnormal regulation of muscle contraction in horses with recurrent exertional rhabdomyolysis.
Topics: Anesthetics, Inhalation; Animals; Biopsy; Caffeine; Central Nervous System Stimulants; Female; Halot | 1999 |
Caffeine- or halothane-induced contractures of masseter muscle are similar to those of vastus muscle in normal humans.
Topics: Aged; Aged, 80 and over; Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Contr | 1999 |
[Caffeine skinned fiber tension test: application to the diagnosis of susceptibility to malignant hyperthermia].
Topics: Caffeine; Disease Susceptibility; Humans; In Vitro Techniques; Malignant Hyperthermia; Muscle Contra | 1999 |
5-HT2 receptor antagonist-mediated inhibition of halothane-induced contractures in skeletal muscle specimens from malignant hyperthermia susceptible patients.
Topics: Adolescent; Adult; Anesthetics, Inhalation; Caffeine; Child; Dose-Response Relationship, Drug; Drug | 1999 |
Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane.
Topics: Anesthetics, Inhalation; Caffeine; Humans; In Vitro Techniques; Malignant Hyperthermia; Methyl Ether | 2000 |
Hypersensitivity of malignant hyperthermia-susceptible swine skeletal muscle to caffeine is mediated by high resting myoplasmic [Ca2+ ].
Topics: Animals; Caffeine; Calcium; Central Nervous System Stimulants; In Vitro Techniques; Malignant Hypert | 2000 |
In vivo whole-body resting energy expenditure and insulin action in human malignant hyperthermia.
Topics: Adult; Anesthetics, Inhalation; Basal Metabolism; Body Composition; Caffeine; Calorimetry, Indirect; | 2000 |
Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility.
Topics: Adolescent; Adult; Aged; Anesthetics, Inhalation; Biopsy; Caffeine; Female; Genetic Predisposition t | 2000 |
Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings, following in vitro exposure to halothane, caffeine and ryanodine.
Topics: Anesthetics, Inhalation; Caffeine; Cell Separation; Halothane; Humans; In Vitro Techniques; Inositol | 2000 |
[Malignant hyperthermia susceptibility in 3 patients with malignant neuroleptic syndrome].
Topics: Adult; Caffeine; Contracture; Disease Susceptibility; Female; Halothane; Humans; Male; Malignant Hyp | 2000 |
[Malignant hyperthermia of Duchenne muscular dystrophy: application of clinical grading scale and caffeine contracture of skinned muscle fibers].
Topics: Animals; Caffeine; False Positive Reactions; Humans; In Vitro Techniques; Malignant Hyperthermia; Mi | 2000 |
An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
Topics: Amino Acid Substitution; Caffeine; Calcium; Cell Line; DNA Mutational Analysis; Female; France; Gene | 2000 |
Xenon does not induce contracture in human malignant hyperthermia muscle.
Topics: Anesthetics, Inhalation; Caffeine; Culture Techniques; Dose-Response Relationship, Drug; Drug Evalua | 2000 |
Effects of a domain peptide of the ryanodine receptor on Ca2+ release in skinned skeletal muscle fibers.
Topics: Action Potentials; Animals; Caffeine; Calcium; Humans; In Vitro Techniques; Magnesium; Malignant Hyp | 2001 |
Homozygous and heterozygous Arg614Cys mutations (1840C-->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family.
Topics: Adult; Anesthetics, Inhalation; Caffeine; DNA Mutational Analysis; Female; Genetic Predisposition to | 2001 |
A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia.
Topics: Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Energy Metabolism; Halothane; | 2001 |
Prolonging viability of swine muscle biopsy specimens in malignant hyperthermia testing.
Topics: Anesthetics, Inhalation; Animals; Caffeine; Central Nervous System Stimulants; Cold Temperature; Ele | 2001 |
Congenital myopathy with central cores and fingerprint bodies in association with malignant hyperthermia susceptibility.
Topics: Adult; Anesthetics, Inhalation; Biopsy; Caffeine; Central Nervous System Stimulants; Halothane; Huma | 2001 |
Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
Topics: Caffeine; DNA; DNA Mutational Analysis; Family Health; Female; Halothane; Humans; Male; Malignant Hy | 2001 |
Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1.
Topics: Animals; Binding Sites; Caffeine; Calcium; In Vitro Techniques; Ion Channel Gating; Kinetics; Magnes | 2001 |
Mutations to Gly2370, Gly2373 or Gly2375 in malignant hyperthermia domain 2 decrease caffeine and cresol sensitivity of the rabbit skeletal-muscle Ca2+-release channel (ryanodine receptor isoform 1).
Topics: Adenosine Triphosphate; Amino Acid Motifs; Amino Acid Sequence; Animals; Binding Sites; Caffeine; Ca | 2001 |
Testing for malignant hyperthermia.
Topics: Anesthesia; Biopsy; Caffeine; Halothane; Humans; Malignant Hyperthermia; Muscle Contraction; Sensiti | 2002 |
Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test.
Topics: Adult; Caffeine; Carbon Dioxide; Case-Control Studies; Disease Susceptibility; Female; Humans; Male; | 2002 |
Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
Topics: Anesthetics, Inhalation; Caffeine; Central Nervous System Stimulants; Genetic Testing; Halothane; Hu | 2002 |
A laboratory animal model for malignant hyperpyrexia.
Topics: Anesthesia; Animals; Arrhythmias, Cardiac; Caffeine; Disease Models, Animal; Drug Interactions; Halo | 1979 |
Malignant hyperthermia.
Topics: Alleles; Anesthesia, General; Caffeine; Halothane; Humans; Malignant Hyperthermia; Muscles | 1978 |
An in-vitro model of malignant hyperthermia: differential effects of inhalation anesthetics on caffeine-induced muscle contractures.
Topics: Anesthetics; Animals; Anura; Caffeine; Calcium; Drug Synergism; In Vitro Techniques; Malignant Hyper | 1978 |
Identification of susceptibility to malignant hyperpyrexia in swine.
Topics: Animals; Caffeine; Disease Models, Animal; Dose-Response Relationship, Drug; Halothane; In Vitro Tec | 1979 |
In vivo neutron activation analysis for bone calcium (INVAA) in malignant hyperthermia susceptible patients.
Topics: Adult; Age Factors; Bone and Bones; Caffeine; Calcium; Female; Halothane; Humans; Male; Malignant Hy | 1979 |
A screening test for the malignant hyperpyrexia phenotype using suxamethonium-induced contracture of muscle treated with caffeine and its inhibition by dantrolene.
Topics: Adolescent; Adult; Caffeine; Child; Dantrolene; Drug Synergism; Humans; Malignant Hyperthermia; Midd | 1979 |
Does prior dantrolene affect the in vitro diagnosis of malignant hyperthermia susceptibility?
Topics: Animals; Biopsy; Caffeine; Dantrolene; Drug Interactions; Halothane; In Vitro Techniques; Malignant | 1979 |
Malignant hyperthermia: diagnosis, treatment and investigations of a skeletal muscle lesion.
Topics: Anesthetics; Animals; Caffeine; Diagnosis, Differential; Disease Models, Animal; Halothane; Humans; | 1979 |
The caffeine test of isolated human muscle in relation to malignant hyperthermia.
Topics: Adolescent; Adult; Caffeine; Child; Child, Preschool; Female; Humans; In Vitro Techniques; Male; Mal | 1977 |
Screening for malignant hyperpyrexia.
Topics: Caffeine; Dose-Response Relationship, Drug; Halothane; Humans; In Vitro Techniques; Malignant Hypert | 1977 |
Drug treatment of malignant hyperpyrexia.
Topics: Caffeine; Calcium; Dantrolene; Humans; Hydantoins; Malignant Hyperthermia; Muscle Contraction; Muscl | 1977 |
The adenosine triphosphate (ATP) depletion test: comparison with the caffeine contracture test as a method of diagnosing malignant hyperthermia susceptibility.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Biopsy; Caffeine; Carbon Dioxide; Child; Dose-Respo | 1976 |
Porcine malignant hyperthermia: effects of temperature and extracellular calcium concentration on halothane-induced contracture of susceptible skeletal muscle.
Topics: Animals; Caffeine; Calcium; Dose-Response Relationship, Drug; Halothane; In Vitro Techniques; Malign | 1975 |
An evaluation of procaine in the treatment of malignant hyperpyrexia.
Topics: Anesthesia, General; Animals; Caffeine; Contracture; Dose-Response Relationship, Drug; Drug Evaluati | 1975 |
Porcine malignant hyperthermia: effect of dantrolene sodium on in-vitro halothane-induced contraction of susceptible muscle.
Topics: Animals; Caffeine; Calcium; Contracture; Dantrolene; Halothane; Hydantoins; In Vitro Techniques; Mal | 1976 |
[3H]ryanodine as a probe of changes in the functional state of the Ca(2+)-release channel in malignant hyperthermia.
Topics: Animals; Biopsy; Caffeine; Calcium Channels; Heterozygote; In Vitro Techniques; Kinetics; Malignant | 1992 |
Dantrolene and azumolene inhibit [3H]PN200-110 binding to porcine skeletal muscle dihydropyridine receptors.
Topics: Animals; Caffeine; Calcium Channels; Dantrolene; Dihydropyridines; Imidazoles; Isradipine; Malignant | 1992 |
W-7, a calmodulin antagonist, and contracture of malignant hyperthermia susceptible skeletal muscle.
Topics: Animals; Caffeine; Calcium; Calmodulin; Dantrolene; Drug Synergism; Halothane; Intercellular Signali | 1992 |
[Two familial cases with exertion-induced heat stroke--relationship to malignant hyperthermia].
Topics: Adult; Biopsy; Caffeine; Family Health; Heat Exhaustion; Humans; Male; Malignant Hyperthermia; Muscl | 1992 |
Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Topics: Adolescent; Adult; Aged; Caffeine; Child; Contracture; Dose-Response Relationship, Drug; Female; Hal | 1992 |
Na(+)-Ca2+ exchange influences halothane and caffeine contractures of malignant hyperthermic skeletal muscle.
Topics: Animals; Caffeine; Calcium; Carrier Proteins; Culture Media; Halothane; Kinetics; Malignant Hyperthe | 1992 |
Evaluation of greyhound susceptibility to malignant hyperthermia using halothane-succinylcholine anesthesia and caffeine-halothane muscle contractures.
Topics: Anesthesia, Inhalation; Animals; Caffeine; Disease Susceptibility; Dog Diseases; Dogs; Genetic Predi | 1992 |
Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
Topics: Caffeine; Culture Techniques; Disease Susceptibility; Halothane; Humans; Malignant Hyperthermia; Mus | 1992 |
Propofol anaesthesia in malignant hyperpyrexia susceptible swine.
Topics: Anesthesia; Animals; Caffeine; Female; Halothane; Injections, Intravenous; Male; Malignant Hyperther | 1992 |
Excitation-contraction coupling in pigs heterozygous for malignant hyperthermia.
Topics: Animals; Caffeine; Electrophysiology; Heterozygote; Malignant Hyperthermia; Muscle Contraction; Musc | 1992 |
Propofol is a 'safe' anaesthetic agent in malignant hyperthermia susceptible patients.
Topics: Adolescent; Adult; Anesthesia, Intravenous; Caffeine; Contracture; Disease Susceptibility; Halothane | 1992 |
[Effects of halothane, caffeine and ryanodine on the intracellular calcium store in blood mononuclear cells].
Topics: Animals; Caffeine; Calcium; Disease Susceptibility; Halothane; Humans; Leukocytes, Mononuclear; Mali | 1992 |
In vitro diagnosis of malignant hyperthermia: influence of electrical stimulation on the contracture response to caffeine.
Topics: Caffeine; Culture Techniques; Dose-Response Relationship, Drug; Electric Stimulation; Humans; Malign | 1992 |
Abnormal rapid Ca2+ release from sarcoplasmic reticulum of malignant hyperthermia susceptible pigs.
Topics: Adenosine Triphosphatases; Animals; Biological Transport; Caffeine; Calcium; Calcium Channels; Filtr | 1991 |
Abnormal human sarcoplasmic reticulum Ca2+ release channels in malignant hyperthermic skeletal muscle.
Topics: Animals; Caffeine; Calcium Channels; Humans; In Vitro Techniques; Ion Channel Gating; Malignant Hype | 1991 |
In vitro correlation between force and energy metabolism in porcine malignant hyperthermic muscle studied by 31P NMR.
Topics: Animals; Biomechanical Phenomena; Caffeine; Calcimycin; Energy Metabolism; Magnetic Resonance Spectr | 1991 |
Interactions of fatty acids with the calcium release channel in malignant hyperthermia.
Topics: Animals; Caffeine; Calcium Channels; Fatty Acids; Halothane; Horses; Humans; Isoproterenol; Lipase; | 1991 |
Evidence for related myopathies in exertional heat stroke and malignant hyperthermia.
Topics: Adult; Biopsy; Caffeine; Disease Susceptibility; Family Health; Female; Halothane; Heat Exhaustion; | 1991 |
Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1990 |
BAY K 8644 and nifedipine alter halothane but not caffeine contractures of malignant hyperthermic muscle fibers.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1991 |
Is resting membrane potential a possible indicator of viability of muscle bundles used in the in vitro caffeine contracture test?
Topics: Caffeine; Electric Stimulation; Halothane; Humans; Malignant Hyperthermia; Membrane Potentials; Musc | 1992 |
In vitro contracture tests in patients with various neuromuscular diseases.
Topics: Adolescent; Adult; Aged; Caffeine; Child; Child, Preschool; Disease Susceptibility; Drug Hypersensit | 1992 |
Why does halothane relax cardiac muscle but contract malignant hyperthermic skeletal muscle?
Topics: Animals; Caffeine; Calcium; Depression, Chemical; Fura-2; Halothane; In Vitro Techniques; Male; Mali | 1991 |
A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia.
Topics: Adolescent; Amino Acid Sequence; Arginine; Base Sequence; Caffeine; Cloning, Molecular; Cysteine; Ex | 1991 |
[A new emphasis on the diagnosis of malignant hyperthermia using the in vitro contracture test?].
Topics: Adolescent; Adult; Caffeine; Child; Child, Preschool; Disease Susceptibility; Halothane; Humans; In | 1991 |
[Diagnosis of malignant hyperthermia. The platelet test versus the in vitro contracture test].
Topics: Blood Platelets; Caffeine; Child; Disease Susceptibility; Halothane; Humans; Male; Malignant Hyperth | 1991 |
[In vitro diagnosis of malignant hyperpyrexia syndrome].
Topics: Adult; Caffeine; Dantrolene; Female; Halothane; Hernia, Inguinal; Humans; In Vitro Techniques; Male; | 1991 |
In vitro contraction test for malignant hyperthermia in patients with unexplained recurrent rhabdomyolysis.
Topics: Adult; Caffeine; Calcium; Disease Susceptibility; Female; Halothane; Humans; Male; Malignant Hyperth | 1991 |
The effect of azumolene on hypercontractility and sarcoplasmic reticulum Ca(2+)-dependent ATPase activity of malignant hyperpyrexia-susceptible porcine skeletal muscle.
Topics: Animals; Caffeine; Calcium-Transporting ATPases; Dantrolene; Halothane; Imidazoles; Malignant Hypert | 1991 |
In vitro contracture testing for determination of susceptibility to malignant hyperthermia: a methodologic update.
Topics: Caffeine; Chromatography, Gas; Contracture; Diffusion Chambers, Culture; Disease Susceptibility; Ele | 1991 |
Pharmacogenetics of caffeine and caffeine-halothane contractures in biopsies of human skeletal muscle.
Topics: Adolescent; Adult; Aged; Aging; Caffeine; Child; Child, Preschool; Female; Genetic Variation; Haloth | 1991 |
Effects of caffeine, halothane, succinylcholine, phenylephrine and isoproterenol on myocardial force of contraction of malignant hyperthermia susceptible swine.
Topics: Animals; Caffeine; Disease Susceptibility; Halothane; Isoproterenol; Malignant Hyperthermia; Myocard | 1991 |
Characterization of swine susceptible to malignant hyperthermia by in vivo, in vitro and post-mortem techniques.
Topics: Administration, Inhalation; Animals; Caffeine; Creatine Kinase; Disease Susceptibility; Genotype; Ha | 1991 |
Altered binding site for Ca2+ in the ryanodine receptor of human malignant hyperthermia.
Topics: Binding Sites; Caffeine; Calcium; Differential Threshold; Humans; Malignant Hyperthermia; Receptors, | 1991 |
Malignant hyperthermia: normal muscle calcium uptake and abnormal caffeine and halothane contractures.
Topics: Adult; Biopsy; Caffeine; Calcium; Disease Susceptibility; False Negative Reactions; Female; Halothan | 1991 |
The caffeine contracture test for malignant hyperthermia: caffeine citrate, caffeine benzoate or caffeine free base?
Topics: Animals; Benzoates; Caffeine; Citrates; Disease Susceptibility; Drug Combinations; Male; Malignant H | 1991 |
Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.
Topics: Animals; Caffeine; Chromosomes, Human, Pair 19; Female; Genetic Linkage; Halothane; Heterozygote; Ho | 1990 |
Calcium handling by platelets from normal and malignant hyperthermia-susceptible pigs.
Topics: Animals; Biological Transport; Blood Platelets; Caffeine; Calcium; Halothane; Malignant Hyperthermia | 1991 |
Malignant hyperthermia in dogs.
Topics: Animals; Biopsy; Caffeine; Crosses, Genetic; Dantrolene; Dog Diseases; Dogs; Female; Halothane; Hear | 1991 |
[Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Caffeine; Child; Female; Genetic Predisposition | 1991 |
Molecular genetics and malignant hyperthermia.
Topics: Caffeine; Genetic Markers; Halothane; Humans; Malignant Hyperthermia; Molecular Biology | 1991 |
A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia.
Topics: Alleles; Caffeine; Child; Female; Genetic Linkage; Genetic Markers; Halothane; Humans; Male; Maligna | 1991 |
Halothane-dependent release of intracellular Ca2+ in blood cells in malignant hyperthermia.
Topics: Animals; Caffeine; Calcium; Cytosol; Disease Susceptibility; Egtazic Acid; Halothane; Humans; Malign | 1990 |
Fiber-type specific caffeine sensitivities in normal human skinned muscle fibers.
Topics: Adenosine Triphosphatases; Adolescent; Adult; Caffeine; Calcium; Child; Disease Susceptibility; Drug | 1990 |
Doxacurium and mivacurium do not trigger malignant hyperthermia in susceptible swine.
Topics: Animals; Caffeine; Female; Isoquinolines; Malignant Hyperthermia; Mivacurium; Muscle Contraction; Ne | 1990 |
[Do neuroleptic malignant syndrome and malignant hyperthermia of anesthesia share a common mechanism?].
Topics: Caffeine; Halothane; Humans; Malignant Hyperthermia; Neuroleptic Malignant Syndrome | 1990 |
Microassay for malignant hyperthermia susceptibility: hypersensitive ligand-gating of the Ca channel in muscle sarcoplasmic reticulum causes increased amounts and rates of Ca-release.
Topics: Adenosine Triphosphate; Animals; Caffeine; Calcium; Calcium Channels; Halothane; Ion Channel Gating; | 1990 |
The importance of calcium ions for in vitro malignant hyperthermia testing.
Topics: Caffeine; Calcium; Contracture; Drug Interactions; Halothane; Humans; In Vitro Techniques; Malignant | 1990 |
Inappropriate use of the t-test.
Topics: Animals; Caffeine; Halothane; Malignant Hyperthermia; Statistics as Topic; Swine | 1990 |
Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia?
Topics: Biopsy; Caffeine; Calcium; Disease Susceptibility; Halothane; Humans; In Vitro Techniques; Malignant | 1990 |
Importance of fasting in the lymphocyte calcium test for malignant hyperthermia.
Topics: Adolescent; Adult; Aged; Caffeine; Calcium; Contracture; Cytoplasm; Fasting; Female; Halothane; Huma | 1990 |
Influence of salbutamol on the in vitro muscle response to caffeine and halothane in malignant hyperthermia.
Topics: Adult; Albuterol; Caffeine; Contracture; Dose-Response Relationship, Drug; Drug Interactions; Female | 1990 |
Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group.
Topics: Animals; Caffeine; Disease Susceptibility; Halothane; In Vitro Techniques; Malignant Hyperthermia; M | 1990 |
Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2.
Topics: Animals; Caffeine; Chromosome Mapping; Chromosomes, Human, Pair 19; Female; Genetic Linkage; Halotha | 1990 |
Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia.
Topics: Caffeine; Disease Susceptibility; False Negative Reactions; Halothane; Humans; In Vitro Techniques; | 1990 |
Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
Topics: Anesthesia, General; Caffeine; Contracture; Disease Susceptibility; Halothane; Humans; Malignant Hyp | 1990 |
Stimulation and inhibition of [3H]ryanodine binding to sarcoplasmic reticulum from malignant hyperthermia susceptible pigs.
Topics: Adenylyl Imidodiphosphate; Alkaloids; Animals; Caffeine; Calcium; Kinetics; Magnesium; Malignant Hyp | 1990 |
Malignant hyperthermia in the otolaryngologic patient: prospective anesthetic and surgical management of eight children.
Topics: Adenoidectomy; Anesthesia, General; Anxiety; Caffeine; Child; Child, Preschool; Contracture; Female; | 1990 |
An association between certain congenital abnormalities and the malignant hyperthermia trait.
Topics: Adolescent; Adult; Caffeine; Child; Child, Preschool; Congenital Abnormalities; Female; Halothane; H | 1990 |
Current diagnostic methods of malignant hyperthermia: an evaluation.
Topics: Caffeine; Chromosomes, Human, Pair 19; Disease Susceptibility; Halothane; Humans; Magnetic Resonance | 1990 |
Effects of the calcium antagonist, TMB-8 on halothane and on caffeine contractures of malignant hyperthermia susceptible skeletal muscle.
Topics: Animals; Caffeine; Calcium Channel Blockers; Gallic Acid; Halothane; In Vitro Techniques; Malignant | 1990 |
Compensatory increase in calcium extrusion activity of untreated lymphocytes from swine susceptible to malignant hyperthermia.
Topics: Animals; Caffeine; Calcium; Disease Susceptibility; Halothane; Lymphocytes; Malignant Hyperthermia; | 1990 |
Abnormal membrane properties of the sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia: modes of action of halothane, caffeine, dantrolene, and two other drugs.
Topics: Animals; Caffeine; Calcium; Dantrolene; Electron Spin Resonance Spectroscopy; Halothane; Intracellul | 1986 |
Effects of halothane, caffeine, dantrolene and tetracaine on the calcium permeability of skeletal sarcoplasmic reticulum of malignant hyperthermic pigs.
Topics: Animals; Caffeine; Calcium; Cell Membrane Permeability; Dantrolene; Halothane; Kinetics; Malignant H | 1987 |
[Central core disease associated with malignant hyperthermia sensitivity].
Topics: Adolescent; Adult; Aged; Biopsy; Caffeine; Child; Child, Preschool; Creatine Kinase; Female; Halotha | 1989 |
Malignant hyperthermia: slow sodium current in cultured human muscle cells.
Topics: Caffeine; Cells, Cultured; Disease Susceptibility; Electric Conductivity; Halothane; Humans; Maligna | 1989 |
The association between the neuroleptic malignant syndrome and malignant hyperthermia.
Topics: Adult; Caffeine; Chlorpromazine; Contracture; Disease Susceptibility; Female; Halothane; Humans; Mal | 1989 |
Effect of diltiazem, verapamil and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible human skeletal muscle.
Topics: Caffeine; Dantrolene; Diltiazem; Disease Susceptibility; Halothane; Humans; In Vitro Techniques; Mal | 1989 |
[The action of ketamine on muscle contractile behavior. In vitro studies on the musculature of subjects susceptible to malignant hyperthermia].
Topics: Caffeine; Disease Susceptibility; Halothane; In Vitro Techniques; Ketamine; Malignant Hyperthermia; | 1989 |
[Malignant hyperthermia; two cases of MH in the presence of general anesthesia and performing caffeine contracture test].
Topics: Adult; Caffeine; Female; Halothane; Humans; Male; Malignant Hyperthermia; Middle Aged; Muscle Contra | 1989 |
The in vitro determination of susceptibility to malignant hyperthermia.
Topics: Animals; Caffeine; Halothane; In Vitro Techniques; Malignant Hyperthermia; Muscle Contraction; Swine | 1989 |
Caffeine sensitivity of sarcoplasmic reticulum of fast and slow fibers from normal and malignant hyperthermia human muscle.
Topics: Caffeine; Humans; In Vitro Techniques; Malignant Hyperthermia; Sarcoplasmic Reticulum | 1989 |
31P-NMR spectroscopy: the metabolic profile of malignant hyperpyrexic porcine skeletal muscle.
Topics: Animals; Caffeine; Halothane; Magnetic Resonance Imaging; Malignant Hyperthermia; Muscles; Phosphoru | 1989 |
Effects of droperidol, haloperidol and ketamine on halothane, succinylcholine and caffeine contractures: implications for malignant hyperthermia.
Topics: Animals; Caffeine; Contracture; Droperidol; Haloperidol; Halothane; Humans; Ketamine; Male; Malignan | 1989 |
Effect of diltiazem and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible porcine skeletal muscle.
Topics: Animals; Caffeine; Dantrolene; Diltiazem; Dose-Response Relationship, Drug; Halothane; In Vitro Tech | 1989 |
[Clinical implications of enhanced caffeine contracture in malignant hyperthermia (MH) and Duchenne muscular dystrophy (DMD)].
Topics: Adolescent; Adult; Aged; Caffeine; Calcium; Child; Child, Preschool; Female; Humans; In Vitro Techni | 1989 |
Standards for halothane/caffeine contracture test.
Topics: Caffeine; Halothane; Humans; Malignant Hyperthermia; Muscle Contraction | 1989 |
Malignant hyperthermia in humans--standardization of contracture testing protocol.
Topics: Biopsy; Caffeine; Clinical Laboratory Techniques; Drug Combinations; Halothane; Humans; Malignant Hy | 1989 |
Fluoxetine treatment of a depressed patient susceptible to malignant hyperthermia.
Topics: Adolescent; Caffeine; Depressive Disorder; Disease Susceptibility; Female; Fluoxetine; Halothane; Hu | 1989 |
Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle.
Topics: Anesthesia; Caffeine; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Interactions; H | 1989 |
Effects of the halothane-sensitivity gene on sarcoplasmic reticulum function.
Topics: Adenosine Triphosphate; Animals; Caffeine; Calcium; Genes; Halothane; Kinetics; Malignant Hypertherm | 1989 |
Anaesthetic-induced increase in ionised calcium in blood mononuclear cells from malignant hyperthermia patients.
Topics: Aminoquinolines; Anesthetics; Caffeine; Calcium; Drug Evaluation; Halothane; Humans; In Vitro Techni | 1987 |
Ca-induced Ca release in malignant hyperthermia-susceptible pig skeletal muscle.
Topics: Adenosine Triphosphate; Animals; Caffeine; Calcium; Halothane; In Vitro Techniques; Kinetics; Malign | 1989 |
Effect of halothane on the Ca2+-transport system of surface membranes isolated from normal and malignant hyperthermia pig skeletal muscle.
Topics: Acetylcholinesterase; Animals; Caffeine; Calcium; Calcium-Transporting ATPases; Cell Membrane; In Vi | 1987 |
Comparative effects of the ionophore A23187 on the mechanical responses of muscle in normal Pietrain pigs and pigs with malignant hyperthermia.
Topics: Animals; Caffeine; Calcimycin; Ethanol; Female; In Vitro Techniques; Malignant Hyperthermia; Muscle | 1986 |
[Contracture test with ionophore A 23187 for the diagnosis of malignant hyperthermia].
Topics: Adolescent; Adult; Caffeine; Calcimycin; Contracture; Female; Halothane; Humans; Male; Malignant Hyp | 1986 |
Malignant hyperthermia in plastic surgery.
Topics: Adult; Caffeine; Child; Child, Preschool; Dermoid Cyst; Disease Susceptibility; Facial Neoplasms; Fe | 1988 |
Calmodulin-antagonist drugs and porcine malignant hyperpyrexia.
Topics: Animals; Caffeine; Calmodulin; Halothane; In Vitro Techniques; Malignant Hyperthermia; Muscle Contra | 1988 |
Age, fiber type composition and in vitro contracture responses in human malignant hyperthermia.
Topics: Adolescent; Adult; Aging; Caffeine; Halothane; Humans; In Vitro Techniques; Malignant Hyperthermia; | 1988 |
[Tests of contracture and sensitivity to malignant hyperthermia in 27 patients].
Topics: Adolescent; Adult; Anesthesia, General; Biopsy; Caffeine; Child; Child, Preschool; Contracture; Crea | 1988 |
Halothane-caffeine contracture testing in neuromuscular diseases.
Topics: Biopsy; Caffeine; Halothane; Humans; Malignant Hyperthermia; Muscle Contraction; Muscles; Neuromuscu | 1988 |
Malignant hyperthermia in a black adolescent. A case report.
Topics: Adolescent; Black People; Caffeine; Humans; Jaw; Male; Malignant Hyperthermia; Muscle Rigidity; Musc | 1988 |
Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs.
Topics: Animals; Benzofurans; Caffeine; Calcium; Disease Susceptibility; Fura-2; Halothane; Malignant Hypert | 1988 |
[Malignant hyperthermia in Austria. II. A comparison of the results of diagnostic test procedures].
Topics: Adult; Caffeine; Creatine Kinase; Disease Susceptibility; Electromyography; Female; Halothane; Human | 1988 |
Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
Topics: Adult; Aged; Caffeine; Disease Susceptibility; Female; Halothane; Humans; In Vitro Techniques; Male; | 1987 |
Prediction of malignant hyperthermia susceptibility by clinical signs.
Topics: Adolescent; Anesthesia, General; Biopsy; Caffeine; Child; Halothane; Humans; Infant; Malignant Hyper | 1987 |
Abnormal relaxation rates in subjects susceptible to malignant hyperthermia.
Topics: Adolescent; Adult; Caffeine; Electromyography; Female; Halothane; Humans; Male; Malignant Hypertherm | 1987 |
Calcium uptake in frozen muscle biopsy sections compared with other predictors of malignant hyperthermia susceptibility.
Topics: Animals; Biopsy; Caffeine; Calcium; Cats; Female; Halothane; Humans; Male; Malignant Hyperthermia; M | 1987 |
In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffeine-suxamethonium.
Topics: Caffeine; Disease Susceptibility; Evaluation Studies as Topic; Halothane; Humans; In Vitro Technique | 1987 |
In vitro diagnosis of susceptibility to malignant hyperthermia: comparison between dynamic and static halothane and caffeine tests.
Topics: Caffeine; Disease Susceptibility; Halothane; Humans; In Vitro Techniques; Malignant Hyperthermia; Mu | 1987 |
Halothane-cooling contractures of mammalian muscles.
Topics: Anesthetics, Local; Animals; Caffeine; Calcium; Cold Temperature; Dantrolene; Dose-Response Relation | 1986 |
Static v. dynamic tests in the in vitro diagnosis of malignant hyperthermia susceptibility.
Topics: Caffeine; Disease Susceptibility; Halothane; Humans; In Vitro Techniques; Male; Malignant Hypertherm | 1986 |
[Contracture response to isoflurane and pentazocine in muscles of a patient with malignant hyperthermia].
Topics: Caffeine; Child; Halothane; Humans; In Vitro Techniques; Isoflurane; Male; Malignant Hyperthermia; M | 1986 |
Investigation of malignant hyperthermia in Sweden.
Topics: Adolescent; Adult; Aged; Caffeine; Child; Female; Halothane; Humans; Male; Malignant Hyperthermia; M | 1986 |
[Detection of peranesthetic malignant hyperthermia by muscle contracture tests and NMR spectroscopy].
Topics: Biopsy; Caffeine; Halothane; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Malignant | 1986 |
Diagnosis of malignant hyperthermia: implications for the military.
Topics: Adolescent; Adult; Caffeine; Halothane; Humans; Male; Malignant Hyperthermia; Military Medicine; Mus | 1985 |
Malignant hyperthermia.
Topics: Adult; Anesthesia; Animals; Caffeine; Child; Creatine Kinase; Disease Susceptibility; Halothane; Hum | 1985 |
Masseter muscle rigidity and malignant hyperthermia susceptibility.
Topics: Caffeine; Child; Creatine Kinase; Female; Halothane; Humans; Male; Malignant Hyperthermia; Masseter | 1986 |
Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
Topics: Blood Platelets; Caffeine; Halothane; Humans; In Vitro Techniques; Malignant Hyperthermia; Muscle Co | 1986 |
Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia.
Topics: Biopsy; Caffeine; Clinical Enzyme Tests; Creatine Kinase; Disease Susceptibility; Humans; In Vitro T | 1986 |
The temperature dependence of halothane-induced contractures of skeletal muscle.
Topics: Anesthetics, Local; Animals; Anura; Caffeine; Calcium; Disease Models, Animal; Halothane; In Vitro T | 1986 |
Porcine malignant hyperthermia: cell injury enhances halothane sensitivity of biopsies.
Topics: Animals; Caffeine; Disease Susceptibility; Halothane; Hybridization, Genetic; In Vitro Techniques; M | 1986 |
Electrophoresis of muscle proteins is not a method for diagnosis of malignant hyperthermia susceptibility.
Topics: Caffeine; Electrophoresis, Polyacrylamide Gel; Halothane; Humans; Malignant Hyperthermia; Molecular | 1986 |
Malignant hyperpyrexia and sudden death.
Topics: Adolescent; Adult; Caffeine; Death, Sudden; Disease Susceptibility; Halothane; Humans; Male; Maligna | 1985 |
In vitro interaction between halothane and succinylcholine in human skeletal muscle: implications for malignant hyperthermia and masseter muscle rigidity.
Topics: Caffeine; Disease Susceptibility; Drug Interactions; Halothane; Humans; In Vitro Techniques; Maligna | 1985 |
Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). European MH Group.
Topics: Caffeine; Disease Susceptibility; Halothane; Humans; Malignant Hyperthermia | 1985 |
Microcalorimetric studies in malignant hyperpyrexia susceptible individuals.
Topics: Blood Platelets; Body Temperature Regulation; Caffeine; Calorimetry; Disease Susceptibility; Halotha | 1985 |
Diltiazem inhibits halothane-induced contractions in malignant hyperthermia-susceptible muscles in vitro.
Topics: Animals; Benzazepines; Caffeine; Depression, Chemical; Diltiazem; Disease Susceptibility; Halothane; | 1985 |
Myoadenylate deaminase deficiency and malignant hyperthermia susceptibility: is there a relationship?
Topics: Adenylate Kinase; Adult; AMP Deaminase; Caffeine; Creatine Kinase; Disease Susceptibility; Female; H | 1985 |
Letter: Procaine and malignant hyperthermia.
Topics: Animals; Caffeine; Drug Interactions; Guinea Pigs; Halothane; Malignant Hyperthermia; Muscle Rigidit | 1974 |
A pharmacological in vitro model of malignant hyperpyrexia.
Topics: Abdominal Muscles; Anesthetics; Animals; Caffeine; In Vitro Techniques; Malignant Hyperthermia; Mode | 1973 |
Letter: Myopathies and malignant hyperpyrexia.
Topics: Caffeine; Calcium; Humans; In Vitro Techniques; Malignant Hyperthermia; Muscle Contraction; Muscles; | 1974 |
Procaine in malignant hyperpyrexia.
Topics: Aged; Caffeine; Female; Halothane; Humans; In Vitro Techniques; Lidocaine; Malignant Hyperthermia; M | 1972 |
Histopathological and neuropharmacological aspects of malignant hyperpyrexia.
Topics: Adult; Anesthesia, General; Caffeine; Child; Child, Preschool; Creatine Kinase; Female; Halothane; H | 1973 |
Recent advances in the understanding of anaesthetic-induced malignant hyperpyrexia.
Topics: Acidosis; Anesthetics; Animals; Anura; Bicarbonates; Caffeine; Calcium; Cold Temperature; Disease Mo | 1973 |
Recent advances in the understanding of anaesthetic-induced malignant hyperpyrexia.
Topics: Anesthesia, General; Animals; Anura; Caffeine; Calcium; Creatine Kinase; Disease Models, Animal; Hum | 1973 |
Biochemical basis of malignant hyperpyrexia.
Topics: Biopsy; Caffeine; Calcium; Cell Membrane; Creatine Kinase; Extracellular Space; Halothane; Humans; I | 1974 |